CA2515292A1 - Random and non-random alkylene oxide polymer alloy compositions - Google Patents

Random and non-random alkylene oxide polymer alloy compositions Download PDF

Info

Publication number
CA2515292A1
CA2515292A1 CA002515292A CA2515292A CA2515292A1 CA 2515292 A1 CA2515292 A1 CA 2515292A1 CA 002515292 A CA002515292 A CA 002515292A CA 2515292 A CA2515292 A CA 2515292A CA 2515292 A1 CA2515292 A1 CA 2515292A1
Authority
CA
Canada
Prior art keywords
composition
mol
kg
random
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002515292A
Other languages
French (fr)
Other versions
CA2515292C (en
Inventor
Tadeusz Z. Wellisz
Timothy C. Fisher
Jonathan K. Armstrong
John Cambridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syncera Inc
Original Assignee
Ceremed, Inc.
Tadeusz Z. Wellisz
Timothy C. Fisher
Jonathan K. Armstrong
John Cambridge
Syncera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US44653403P priority Critical
Priority to US60/446,534 priority
Application filed by Ceremed, Inc., Tadeusz Z. Wellisz, Timothy C. Fisher, Jonathan K. Armstrong, John Cambridge, Syncera, Inc. filed Critical Ceremed, Inc.
Priority to PCT/US2004/004174 priority patent/WO2004071452A2/en
Publication of CA2515292A1 publication Critical patent/CA2515292A1/en
Application granted granted Critical
Publication of CA2515292C publication Critical patent/CA2515292C/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0084Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0094Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09JADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J153/00Adhesives based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Adhesives based on derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • C11D3/3703Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707Polyethers, e.g. polyalkyleneoxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2666/00Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
    • C08L2666/02Organic macromolecular compounds, natural resins, waxes or and bituminous materials
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2666/00Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
    • C08L2666/02Organic macromolecular compounds, natural resins, waxes or and bituminous materials
    • C08L2666/14Macromolecular compounds according to C08L59/00 - C08L87/00; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S606/00Surgery
    • Y10S606/907Composed of particular material or coated
    • Y10S606/91Polymer

Abstract

A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.

Description

RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY
COMPOSITIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
s This application claims the benefit of provisional U.S. Patent Appln. No.
60/446,534, filed February 12, 2003; it is also related to the patent application fatty. dkt. 4278-6) entitled "Random Alkylene Oxide Copolymers With Medical and Surgical Utilities" and being filed on February 12, 2004. Both applications are incorporated by reference.
FIELD OF THE INVENTION
The invention relates to a composition comprised of (i) at least one random copolymer comprised of ethylene oxide and other alkylene oxides) and (ii) at least one non-random polymer comprised of one or more 1.5 poly(alkylene oxides (e.g., homopolymers and/or block copolymers).
BACKGROUND OF THE INVENTION
In the medical and surgical fields, there has been an unmet need for compositions with handling characteristics that range from a viscous oil to a 2o hard wax. Desirable compositions would have one or more of the following properties: biocompatibility, non-metabolizable under physiological conditions, low toxicity and corrosiveness, readily eliminated from the body in unmodified form, easy and inexpensive to manufacture and store, long lived, and variable viscosity and hardness. Preferably, such compositions would be resorbed and 25 readily eliminated by the body after they had served their intended purpose.
Such compositions would have a wide range of uses. For uses in the surgical field, compositions which have handling characteristics resembling a hard, adherent wax could be useful as a hemostatic agent that could be used to prevent bleeding from the surfaces of bones. Compositions with oily, greasy, or 3o waxy characteristics (in ascending degrees of hardness) can be used as lubricants of surgical instruments and implants. Applications would include use as a carrier or excipient for particulate implantable materials, bioactive agents, and other pharmaceutical agents. The compositions are also suitable as a matrix for particulate material, adhesive/cohesive, filler, and/or lubricant;
they may also be used as dispersing or suspending agents, emulsifiers, extenders, thickeners, and/or bodying agents for compositions, in particular for cosmetic and pharmaceutical formulations.
Until our discovery, there were no biocompatible, substantially non-toxic, water-soluble compositions available with handling characteristics that range from a grease to a wax over a temperature range from about 25°C to about 37°C for medical and surgical applications, which can be formulated to be 1 o substantially free of water (e.g., less than about 5% or about 1 % water).
All previously known water-soluble compositions with such handling characteristics and intended for medical or surgical applications contained water in their formulation.
Currently, the medical and surgical need for the appropriate formulations is being met in a number of different and less than acceptable ways. Most have the problem of either not being completely biocompatible or not having handling characteristics that are well suited for their intended application. Beeswax, commonly used as a bone hemostatic agent, is non-resorbable, interferes with bone healing, and causes inflammatory reactions. Compounds derived from 2o biological sources, such as collagen, have the potential to cause immune reactions and may even have the potential to spread infectious agents. Many compounds in use fall into the category of hydrogels. Hydrogels consist of a three dimensional network of hydrophilic polymer chains in an aqueous medium that are cross-linked through either chemical or physical bonding.
2s Theoretically, at least, the network is infinite and the polymer chains are effect-tively a single molecule. By definition hydrogels contain at least 10% water by total weight (or volume); but more commonly contain 10 to 50 times more water than polymer (w/w/ or w/v). Hydrogels in general do not have ideal physical characteristics for a material that needs to be handled and manipulated into 3o position. They are typically elastic but not plastic, lacking malleability and ductility, and are often labile when exposed to compressive, tensile or shearing forces, leading to irreversible fracturing or tearing of the material. The water within hydrogels also may affect the lifetime of bioactive agents. Hydrocarbon compounds, either petroleum based (e.g., paraffin, petrolatum) or from other sources such as beeswax or plant-derived waxes, have the appropriate handling characteristics, but are not water soluble. Silicon oils and silicon gels s are neither biologically inert nor water soluble. Thus, suitable polymers for therapeutic use remain to be discovered.
In the fields of surgery and dentistry, there is a need for an implantable material that contains a particulate component that can serve as a framework for tissue ingrowth. The particulate component can be selected from a broad 1o range of natural and synthetic implantable substances, including but not limited to native autogenous bone or cartilage, bone or cartilage from other sources that is either grafted directly or after processing, collagen, hydroxyapatite, poly-methylmethacrylate (PMMA), polytetrofluoroethylene (PTFE), polyethylene, and dimethylpolysiloxane.
~ 5 The performance of particulate implants is markedly improved by the addition of a matrix to temporarily adhere the particles to one another and to form a putty that serves to improve the handling characteristics and acts as a delivery system. The majority of matrices in use or disclosed in the prior art are aqueous solutions or hydrogels including collagen, glycerol, polysaccharides, 2o mucopolysaccharides, hyaluronic acid, plasdones, and polyvinylpyrrolidones (PVP).
Collagen, in the form of gelatin, has been used in ARTEPLAST~ from Rofil Medical International. It is an injectable material comprised of micro-spheres of PMMA suspended in a gelatin solution. Following implantation, the 25 gelatin is resorbed and replaced by native collagen. Another formulation, ARTECOLL~ is a product currently available in Europe and Canada. It is comprised of smooth PMMA spheres, suspended in bovine collagen from a closed pharmaceutical herd at a concentration of 25% PMMA/75% collagen, by weight with 0.3% lidocaine. Because ARTECOLL~ contains bovine collagen, 3o testing for allergy to such collagen is recommended. Bovine collagen carries the risk of an immunogenic reaction by the recipient patient. Recently, it has been found that a disease of cattle, bovine spongiform encephalopathy (BSE) is transmitted from bovine tissue to humans. Thus, bovine collagen carries a risk of disease transmission and is not a desirable matrix for allograft bone.
Human collagen is free of these animal-based diseases. However, collagen absorbs slowly in the human body, particularly in a bony site with a low degree of vascularity.
Glycerol is used as a matrix for demineralized allograft bone in the form of a gel. For example, GRAFTON from Osteotech is a simple mixture of glycerol and lyophilized, demineralized bone powder (U.S. Patent 5,073,373).
GRAFTON works well to allow the surgeon to place the allograft bone at the 1 o site. But glycerol has a very low molecular weight (92 daltons) and is very soluble in water, the primary component of the blood which flows at the surgical site. Glycerol also experiences a marked reduction in viscosity when its temperature rises from room temperature (typically 22°C in an operating room) to the patient's body temperature (typically 37°C). This combination of high water solubility and reduced viscosity causes the allograft bone with a glycerol matrix to be runny and to flow away from the site almost immediately after placement. This prevents the proper retention of the allograft bone within the site as carefully placed by the surgeon. The use of the low molecular weight glycerol carrier also requires a high concentration of glycerol to be used to 2o achieve the bulk viscosity. Glycerol and other low molecular weight organic solvents are also toxic and irritating to the surrounding tissues. U.S. Patent 6,306,418 describes the use of glycerol as the matrix for TEFLON particles in the field of urology.
Surgical implantation of artificial sphincters has often been employed to treat patients suffering from urinary incontinence. The most common and widely used method to treat patients with urinary incontinence is periurethral injection of a composition commercially sold as POLYTEF, which is a paste comprising a 1:1 by weight mixture of glycerin matrix and TEFLON particles.
After injection, however, the glycerin is readily dissipated into the body over a 3o period of time and then metabolized or eliminated, leaving only the TEFLON
particles. A drawback of such a paste is that the size of the particles is suffi-ciently small so as to allow them to migrate to other locations of the body such as the lungs, brain, etc. TEFLON particles have been known to induce tissue reaction and form TEFLON-induced granulomas in certain individuals. This tissue reaction to TEFLON also has caused concerns for the patient's health.
U.S. Patent 4,191,747 discloses a bone defect treatment with denatured bone meal freed from fat and ground into powder. The bone meal is mixed with a polysaccharide in a solution of saline and applied to the bone defect site.
U.S. Patent 5,290,558 discloses a flowable, demineralized bone powder composition using an osteogenic bone powder mixed with a low molecular weight polyhydroxy compound possessing from 2 carbons to about 18 carbons 1 o including a number of classes of different sugars such as monosaccharides, disaccharides, water-dispersible oligosaccharides, and polysaccharides.
U.S. Patent 5,356,629 discloses making a rigid gel in the form of a bone cement to fill defects in bone by mixing biocompatible particles preferably PMMA coated with polyhydroxyethylmethacrylate in a matrix (e.g., hyaluronic acid) to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomeric form or in polymeric form preferably having a molecular weight not greater than about one million daltons. It is noted that non-bioabsorbable but biocompatible particles can be derived from xenograft bone, homologous bone, autogenous 2o bone, as well as other substances. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, in addition to morselized cancellous bone, aspirated bone marrow, and other autogenous bone sources. This is a cement used for implantation of hip prosthesis.
Ersek et al. describe the clinical use of soft particles delivered as a biphasic hydrogel material (Plast. Reconstr. Surg. 95:985-992, 1995). The material comprises solid particles of dimethylpolysiloxane ranging in size from 100 micron to 600 micron suspended in a hydrogel of the plasdone family.
BIOPLASTIQUE~ material from Uroplasty, a biphasic material, consists of solid silicone particles, ranging from 100 microns to 400 microns in size, so suspended in PVP. But this material elicits a low-grade inflammatory response upon injection. In a rabbit model, the hydrogel matrix is reabsorbed by the body within 96 hours and eliminated in an intact form by the kidneys. The hydrogel matrix is replaced by fibrin and inflammatory cells. Fibroblasts are recruited into the area by 14 days and begin to replace the fibrin bed with a collagen matrix.
The collagen encapsulates and localizes the silicone, and animal studies have not shown any evidence of foreign body migration. Deposition of collagen progresses, replacing the organic component of the material in a ratio slightly greater than 1:1. Connective tissue cells develop and replace about 30% of the matrix with host collagen fibrils. At 382 days, fibrosis was complete and each individual particle appeared to be encased in its own fibrous capsule. This material has the distinct disadvantage of using silicone, which may be of 1 o concern when evaluating long-term safety.
U.S. Patent 5,641,502 discloses a material comprising (i) a polymer derived from hydroxyacids, tactones, carbonates, etheresters, anhydrides, orthoesters, and copolymers, terpolymers and/or blends thereof and blended with (ii) at least one surface active agent which is from 2% to 55% by weight block copolymer of polyoxyethylene and polyoxypropylene. Additionally, a leaching agent from 0% to 70% by weight may be included in the blend to provide a porous microstructure.
Poloxamer-based thermoreversible hydrogels are being developed for use as a drug delivery system. The cooled poloxamer solution containing the 2o drug is liquid at less than 10°C. It is easily administered to the desired location in the body and the drug-containing solution forms a hydrogel as it warms to 37°C. The solidified gel remains at the site, slowly releasing the drug by diffusion and/or gradual solubilization of the gel matrix. Such compositions are distinguished from our invention because they do not include a random copolymer component, and do not have the wide variety of utilities disclosed herein.
U.S. Patent 6,281,195 discloses a poloxamer hydrogel matrix for the delivery of osteogenic proteins. In particular, poloxamer 407 (PLURONIC~
F127) is used in the form of a hydrogel. But hydrogels have disadvantages if 3o used as the matrix instead of the present composition.
Therefore, in the field of surgery, a biocompatible, substantially non-toxic composition with adhesive and cohesive properties is needed. Hemostasis is an example of an application of such a composition. Bone is a structure with a rich blood supply. Blood within bone typically circulates through a system of canals and within the bone marrow and, as such, hemostasis using traditional methods, such as an electrocautery, is ineffective. Traditionally, bone hemo-stasis is obtained by applying a formulation primarily composed of beeswax onto the cut surface of the bleeding bone. The beeswax adheres to the bone and serves to act as a tamponade of the canals and bone marrow space, eventually leading to the clotting of the blood. Unfortunately, beeswax is not cleared by the body and acts to interfere with bone healing and inflammatory 1 o reactions are known.
Provisional U.S. Appln. No. 60/162,347 discloses a water-soluble wax for use as a bone hemostasis agent whose handling characteristics aim to simulate those of beeswax. The application of alkylene oxide block copolymers over the bleeding sites of the bone for hemostasis was described. Advantages over prior art methods include the finding that bone growth was not inhibited, and the water-soluble composition was resorbed and excreted. The preferred material described is a 9:1 blend by weight of two block copolymers: poloxamer 235 (PLURONIC~ P85) and poloxamer 238 (PLURONIC~ F88). But a random copolymer component was neither taught nor suggested. Blending poloxamer 235 and poloxamer 238 requires a precise combination of ingredients and snap cooling to preserve the blend, which is not a readily static mixture, and obtain the desired mechanical properties.
The formulations of bone hemostasis agents in the prior art lack one or more of the following attributes: biocompatibility, superior handling character istics, and easy manufacture and storage. In contrast, preferred embodiments of the invention provide a biocompatible, substantially non-toxic, stable (i.e., non-metabolizable and readily eliminated) composition with superior handling characteristics.
It is an objective of the invention to provide a composition with superior so properties for medical and surgical applications. Biocompatibility, substantial non-toxicity, water solubility, desirable handling properties (e.g., hardness, ductility, malleability), emulsification, filling, slipperiness (e.g., lubrication), surface activity (e.g., surface activity), tackiness (e.g., adhesion, cohesion), and thickening are characteristics of particular interest. Further advantages of the invention are described.
SUMMARY OF THE INVENTION
The invention relates to compositions which may be used in medicine, surgery, dentistry, and various other commercial (i.e., non-medical) utilities.
Processes for making and using this product and related products are provided.
A polymeric composition may be comprised of (i) at least one random io copolymer comprised of ethylene oxide and one or more other alkylene oxides) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxides. The non-random polymer may be a homopolymer or a block copolymer of at least two poly(alkylene oxides. The composition may be a polymer alloy. The composition can be biocompatible, substantially non-toxic to living tissue, substantially non-metabolizable under physiological conditions, readily eliminated in unmodified form by the body, or any combination thereof.
The composition can be formulated to be water soluble, but contain no water (i.e., substantially anhydrous except for minor amounts of absorbed water).
The composition may have a consistency of a viscous oil to a hard wax (including a 2o grease or paste). Water may be added prior to use or absorbed in the body, but it is preferred to formulate the composition as a flowable liquid with less than about 5% or 1 % water before use in the body or further formulation.
Generally, it is not considered a hydrogel, especially before use in the body or further formulation.
Choice of the other alkylene oxide(s), molecular mass, mass ratio, and procedures during manufacture can affect the compound's properties: e.g., hardness, adhesiveness, cohesiveness, ductility, malleability, and hardness.
For example, "working" the composition may change its characteristics by homogenizing its internal structure. Handling characteristics may be similar so when compared between ambient temperature (e.g., 20°C to 25°C) and body temperature (e.g., 37°C or 40°C).

i Such products may be administered to the body (e.g., applied topically to the skin or other exposed tissue, depot or suppository, implanted or placed therein, ingested, injected). Biocompatibility and substantial non-toxicity are desirable properties for such applications.
s Another composition may be made by suspending (a) particles in (b) a carrier comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxides) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxides. This material may be adhered to hard tissue (e.g., tooth, bone, cartilage) with minimal adverse o reaction by the tissue, the matrix may be resorbed to leave behind a porous framework of solid particles, and tissue may grow within the pores. In a preferred embodiment, the composition is made by mixing at an about 1:3 mass ratio of poloxamer 188 with 22K random alkylene oxide copolymer (AOC) to form a soft wax.
15 A polymeric alloy composition may be made by blending (a) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxides) and (b) at least one non-random polymer comprised of one or more poly(alkylene oxides.
An objective of the invention is to provide carriers and excipients. They 2o may take advantage of any one of the beneficial properties described herein to deliver a therapeutic (e.g., bioactive agent, device, instrument) in the body of a human or animal. For example, the excipient may act as a lubricant to assist the passage or placement of the therapeutic in the body or a part thereof.
A further objective is to provide for an oral composition to be used as an 25 excipient or as a laxative. In like fashion, it is intended to provide a component for cosmetic and pharmaceutical formulations for topical application, particularly for uses in which drawing fluid away from the application site is desirable.
Another objective is to provide a waxy material for utilities such as lost wax casting and water-soluble crayons. The composition may be used as a so cleanser or stain remover. Lubricants, either flowable liquid or solid, to ease passage and to decrease friction are provided.

Further aspects of the invention will be apparent to a person skilled in the art from the following detailed description and claims, and generalizations thereto. In particular, a reference to a "composition" in the context of this invention includes compositions containing only polymers (e.g., blend or alloy 5 of random copolymer and non-random polymer) as well as compositions with non-polymeric additives (e.g., bioactive agents, medical/surgical devices, implants, instruments, solid or porous particles, therapeutic or non-therapeutic products, and combinations thereof).
io BRIEF DESCRIPTIONS OF THE DRAWINGS
Figure 1 illustrates crystals of compositions made with random AOC
(about 22,000 g/mol; 50:50 mass ratio of ethylene oxide to propylene oxide) and block AOC, poloxamer 188 (PLURONIC~ F68), in the following proportions of non-random polymer to random copolymer (F68:22K random AOC): (A) 2:98, (B) 5:95, (C) 10:90, (D) 20:80, (E) 30:70, (F) 40:50, (G) 50:50, (H) 60:40, (I) 70:30, (J) 80:20, (K) 90:10, or (L) 98:2. Single crystals were formed in all of the compositions, without gaps appearing between the crystals (i.e., a single component solid). This shows that they were all comprised of a compatible, homogeneous blend. Spherulite sizes did not appear to vary between mass 2o ratios of 5:95 and 50:50. Above a mass ratio of 60:40, crystal size increased and spherulite rings and fractures became apparent. Fractures gave an opaque appearance to the solid sticks. They were clearly seen as black lines within and between the crystals for mass ratios between and 70:30 and 98:2.
Figure 2 illustrates crystals of compositions with the following random AOC and non-random polymer in equal mass proportions: (A) 3.5K PEO homo-polymer and 12K random AOC, (B) poloxamer 188 and 12K random AOC, (C) 35K PEO homopolymer and 12K random AOC, (D) 2K PEO homopolymer and 3.9K random AOC, and (E) 7.5K PEO homopolymer and 3.9K random AOC.
Figs. 2A-2B are examples of compatible, miscible blends under the conditions 3o and at the resolution used here. Spherulites without gaps between the crystals show that only a single phase was observed. Figs. 2C-2E are examples of incompatible (immiscible) blends. There are clearly multiple phases observed, PEO in the melt phase forms discreet spherical crystalline droplets as it cools.
Fig. 2D illustrates the presence of some compatible (fibrous) regions. Under the definition of AOC alloy used herein, Figs. 2A-2B illustrate examples of polymer alloys but incompatible compositions are illustrated in Figs. 2C-2E.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
Those skilled in the art will appreciate that the compositions described here may be utilized for a wide variety of applications. The present invention provides for water soluble, biocompatible, substantially non-toxic, substantially 1o non-metabolizable, and/or readily eliminated compositions. Compositions which are polymer alloys are preferred. A "polymer alloy" defined under the conditions described here is a macroscopically homogeneous composition of two or more different species of polymers which is comprised of compatible polymer blends and miscible polymer blends, but this definition excludes incompatible polymer 15 blends. The specified attributes and handling characteristics of the composition can be designed as shown herein by appropriate selection of polymers, as well as their molecular masses and ratios.
The composition may be made by blending a polymeric material comprising (i) at least one random alkylene oxide copolymer (random AOC) 2o and (ii) at least one non-random alkylene oxide polymer. The random AOC may be comprised of ethylene oxide and one or more alkylene oxide(s). The non-random polymer may be homopolymer (AOH) and/or copolymer (block AOC).
Poly(alkylene oxides (PAO) which are also known as polyoxyalkylenes (POA) are made by the polymerization of alkylene oxides (e.g., ethylene oxide, 25 propylene oxide, butylene oxide). A homopolymer is formed only from one type of alkylene oxide while a copolymer is formed from two or more different alkylene oxides, known as alkylene oxide copolymers (AOC). Examples of the former are polyethylene oxide) (PEO), which is a polymer of ethylene oxide (EO), and polypropylene oxide) (PPO), which is a polymer of propylene oxide 30 (PO). Polyethylene oxide) is also commonly known as polyethylene glycol (PEG) or polyoxyethylene (POE). The molecular weight of such polymers is generally characterized as the average of a distribution of lengths (or repeat units). PEO is amphiphilic, extremely hydrophilic, water soluble, biocompatible, and substantially non-toxic and is produced commercially in a wide range of molecular weights (200 g/mol to 10 million g/mol). Low molecular weight forms of POE below 600 g/mol (i.e., oligomeric forms with less than 14 EO monomer units on average) are low-viscosity liquids at room temperature; PEO is a solid at 25°C above 600 g/mol. PPO differs from PEO in that it is hydrophobic, generally insoluble in water except at low molecular weights (less than about kg/mol), and is liquid at 25°C even at high molecular weights (e.g., 6 kg/mol).
The homopolymer may have a molecular mass of at least about 1 kg/mol, 1 o about 2 kg/mol, or about 5 kg/mol; the molecular mass may also be not more than about 10 kg/mol, about 20 kg/mol, or about 50 kg/mol. The compound may be further described by intermediate ranges using the aforementioned upper and lower limits.
In addition to the standard linear forms, branched or star forms of poly(alkylene oxides are produced by initiating the polymerization reaction with a polyfunctional initiator with multiple hydroxyl-, amino-, or thiol-groups each of which can serve as a starting point for polymer chain growth. For example, the use of glycerol (three hydroxyl groups) as an initiator results in a three-armed branched polymer, while pentaerythritol results in a four-armed polymer. PEO
2o molecules of this type are available commercially (e.g., the SunbrightTM
series, NOF Corporation, Japan) with anywhere from three to more than one hundred arms. Conventionally, polymers of this type with 3 to 10 arms are termed "branched" while those with more than 10 arms are termed "star" polymers.
"Comb" copolymers are similar to branched and star forms, but the initiator for 2s comb copolymers is a polyfunctional polymer with multiple hydroxyl-, amino-, or thiol-groups spaced along the initiator backbone, each of which can serve as a staring point for polymer chain growth. "Graft" copolymers are made by the addition of pendant polymer chains along a polymer backbone that possesses unsaturated C=C bonds or pendant functional groups (e.g., hydroxyl) from 3o which pendant chains can be added by using a reactive monofunctional polymer chain.

All poly(alkylene oxides contain, in addition to multiple alkylene oxide-derived repeat units, a single residue corresponding to the molecule used to initiate the polymer synthesis. For linear polymers, this may be an alkylene glycol corresponding to the alkylene oxide used for the synthesis (e.g., ethylene glycol and ethylene oxide, respectively) and thus the initiator-derived residue will be indistinguishable from the other repeat units in the polymer chain.
But small molecules other than alkylene glycols are often used as initiators, examples include methanol or N-butanol (for linear polymers) and trimethylol propane, glycerol, and pentaerythritol (for branched polymers) or ethylene io diamine. The mass of initiator relative to the mass of the final polymer chain is generally very small and can usually be neglected. Thus, the term poly(alkylene oxide) is used here in its customary sense, and includes both poly(alkylene oxides initiated with an alkylene glycol molecule and poly(alkylene oxides initiated with another small molecule.
Water-soluble poly(alkylene oxides are substantially non-toxic when applied to the skin or taken orally, and PEG and some poloxamers (e.g., F68 or poloxamer 188) have been evaluated for medical and surgical applications, and demonstrated to be suitable for parenteral use.
2o RANDOM ALKYLENE OXIDE COPOLYMER
Random AOC preferably has a molecular mass from about 1 kg/mol to about 1000 kg/mol (i.e., average molecular mass of a distribution of polymers).
It may have a molecular mass of at least about 5 kg/mol, about 10 kglmol, or about 20 kg/mol; the molecular mass may also be not more than about 25 kg/mol, about 50 kg/mol, or about 200 kg/mol. The mass ratio of ethylene oxide to the other alkylene oxides) preferably is from about 5:95 to about 95:5. It may have a mass ratio of at least about 10:90, about 25:75, or about 40:60;
the mass ratio may also be not more than about 60:40, about 75:25, or about 90:10. The compound may be further described by intermediate ranges using 3o the aforementioned upper and lower limits.
A preferred random AOC is a copolymer of ethylene oxide and CnH2n0, where n = 3 to 6. In a particular embodiment, the molecular mass may be from about 15 kg/mol to about 30 kg/mol. Preferably, the molecular mass is at least about 20 kg/mol and/or not more than about 25 kg/mol and has a mass ratio of ethylene oxide to propylene oxide that is substantially equimolar.
In contrast to block AOC, a random copolymer of alkylene oxides) can be synthesized directly from an appropriate mixture of alkylene oxides, and thus the different alkylene oxide molecules are added to the polymer chain in a random sequence. The random AOC may be copolymers) of EO and PO.
Random EO/PO copolymers have a certain combination of properties which distinguish them from EO and PO homopolymers and block AOC, and which 1o make them uniquely useful as excipients for certain pharmaceutical applications. The most important of these is that they combine two of the desirable properties of PEO and PPO - i.e., they are liquids at room temperature and above over a wide range of molecular weights, but are water soluble. In contrast, except at very low molecular weights (less than 1000 15 g/mol), PPO is not water soluble and POE is a solid. Also, unlike most block copolymers, random AOC do not in the pure state self-associate to form structured domains or a crystalline structure (hence their liquid nature).
Like all other PAO, they are soluble in selected organic solvents, able to solubilize many organic and inorganic substances including hydrophobic drugs that are 2o poorly soluble in water, and have very low toxicity.
There is some evidence that small PEO molecules (600 g/mol or less) may be metabolized in vivo to produce oxalate, which is toxic. But larger PAO
are known to be effectively inert and non-metabolizable in vivo, and are excreted unchanged. This provides a further advantage of the higher molecular 2s weight random PAO liquids vs. liquid PEO.
A preferred embodiment uses a random alkylene oxide copolymer with a molecular weight of about 22 kg/mol (22K random AOC) and an EO:PO mass ratio of about 50:50. Such a compound is commercially available from BASF
Corporation as PLURACOL~ V-10. According to its manufacturer, V-10 was 3o developed specifically for use in water-glycol fire-resistant hydraulic fluids and is additionally suitable as a water-soluble, cutting and grinding fluid and in various metal working applications. Furthermore, the manufacturer discloses that complete toxicity information on V-10 has not yet been fully developed and that the normal precautions exercised when handling any chemical should be used when working with V-10: e.g., eye protection should be used and prolonged contact with the skin should be avoided. Another preferred embo-5 diment is a random alkylene oxide copolymer with a molecular weight of about 12 kg/mol (12K random AOC) and a mass ratio EO:PO of about 75:25.
Random AOC are produced by several manufacturers including BASF, Dow Chemical, and Sigma/Aldrich under the trade names PLURADOT~, PLURACOL~, SYNALOX~ EPB, and EMKAROX~ among others. They are 1o available in a range of EO:PO ratios and molecular weights (e.g., 1000 to 22,000 g/mol) and in linear and branched geometries, and are commonly characterized by their viscosity rather than molecular weight. Dow Chemical provides a number of random AOC with molecular weights in the range of 1,500 to 4,900 including those with the following codes: EP 530, EP 1730, EP
~5 435, EP 1660, 15-200, 112-2, UCON 50-HB-5100, and UCON 50-HB-660.
Sigma/Aldrich provides a number of random AOC with molecular weights in the range of 2,500 to 12,000 including those with the following codes: 43,819-7, 43,820-0, 43,818-9, 40,918-9. Medical applications for PAO have been focused on block AOC. In contrast, the use of random AOC has almost exclusively been 2o restricted to nonmedical applications, and their potential for providing medical benefits has been largely overlooked.
BLOCK ALKYLENE OXIDE COPOLYMER
Block AOC may be linear or branched, and preferably has a molecular mass from about 1 kglmol to about 100 kg/mol (i.e., average molecular mass of a distribution of polymers). It may have a molecular mass of at least about 2 kglmol, about 4 kg/mol, about 6 kg/mol, or about 10 kg/mol; the molecular mass may also be not more than about 10 kg/mol, about 15 kg/mol, about 20 kg/mol, or about 50 kg/mol. A preferred block AOC is a copolymer of ethylene oxide and C"H2"O, where n = 3 to 6 (propylene oxide is preferred). The mass ratio of ethylene oxide to the other alkylene oxides) preferably is from about 5:95 to about 95:5. It may have a mass ratio of at least about 10:90, about 25:75, or about 40:60; the mass ratio may also be not more than about 60:40, about 75:25, or about 90:10. The compound may be further described by intermediate ranges using the aforementioned upper and lower limits. Preferred embodiments use a block alkylene oxide copolymer with (1 ) a molecular mass from about 6 kg/mol to 10 kg/mol and an EO:PO mass ratio from 60:40 to 9.0:10 or (2) a molecular mass from about 6 kg/mol to 10 kg/mol and an EO:PO mass ratio from 60:40 to 90:10.
Block copolymers are synthesized sequentially. First, a central block is commonly polymerized from one type of alkylene oxide (e.g., PO), then one or 1o more outer blocks are added to the ends in a second polymerization step using another alkylene oxide (e.g., EO). Poloxamers (e.g., PLURONIC~ copolymers from BASF) are linear A-B-A triblock copolymers of EO and PO having the general formula (EO)x(PO)Y(EO)X, where x, y are the average number of EO
and PO monomer units in the block. A hydrophobe of the desired molecular weight is made by the controlled addition of propylene oxide to the two-hydroxyl groups of propylene glycol; ethylene oxide is then added to sandwich the hydrophobic block between hydrophilic blocks. The hydrophilic blocks constitute from 10% to 80% by weight of the final molecule. Poloxamers are available in a range of molecular weights from 1,100 to 15,000 g/mol and 2o PO:EO ratios of 9:1 to 2:8. Meroxapols (e.g., PLURONIC~ R from BASF) are linear triblock copolymers similar to poloxamers but with a reversed (B-A-B) structure and hence the general formula (PO)y(EO)X(PO)y. A hydrophile of the desired molecular weight is made by the controlled addition of ethylene oxide to ethylene glycol; propylene oxide is then added to create hydrophobic blocks on the outsides of the central hydrophilic block. The physical properties of block copolymers range from low-viscosity liquids to pastes to solid, depending upon the precise combination of molecular weight and EO:PO ratio (higher molecular weight and higher EO proportion increasing the melting point). See review by Schmolka (J. Am. Oil Chem. Soc., 54:110-116, 1977).
3o In BASF's PLURONIC~ code, the alphabetical designation is derived from the physical form of the product at room temperature: L for liquids, P
for pastes, and F for flake (solid) forms. Preferred block AOC are P108, P188, P238, P288, P338, P237, P335, and P407. In the numerical designation, the first digit (or the first two digits in a three numeral code) multiplied by indicates the approximate molecular weight of the hydrophobe. The last digit multiplied by 10 indicates the approximate percentage (w/w) of the hydrophile in the PLURONIC~ copolymer.
Poloxamer 188 (PLURONIC~ F68) (8350 g/mol, 80% POE), has been used for topical wound cleaning and has been approved for intravenous use as an emulsifier for perfluorocarbon oxygen-carrying formulations. Aqueous solutions of a poloxamer such as poloxamer 407 (PLURONIC~ F127) (12,500 1 o g/mol, 70% POE) at a sufficiently high concentration (typically greater than about 30% w/v) are used as hydrogel formulations for drug delivery. These are preferred block AOC.
Poloxamines (e.g., TETRONIC~ block copolymers from BASF), are 4-armed symmetrical poly(alkylene oxide) block polymers prepared using an ethylene diamine initiator with the general formula [(EO)X (PO)Y]2-NCH2CH2N-[(PO)y-(EO)X]2, and are another example of an alkylene oxide copolymer that may be used to make the composition. Reverse poloxamines, in which the four PEO blocks are added before the four PPO blocks, can also be used.
2o BLENDING RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMERS
A discovery that forms one basis for the present invention is that certain random AOC are capable of forming either compatible or miscible blends (i.e., alloys) with selected solid AOH and block AOC. This previously unrecognized property differentiates random AOC from other liquid polymers, such as low molecular weight PEO and PPO, which do not form alloys with solid PEO or poloxamers, or liquid poloxamers, which will generally only form alloys with closely related copolymers, such that no advantage is to be gained by the mixing. Adjustment of the mass ratio between non-random polymer and random copolymer can be used to produce compositions of varying hardness so and viscosity. For compositions, the mass ratio (block AOC : random AOC) may be 1:199 to 199:1. A mass ratio of about 2:98 with 22K random AOC is no longer a flowable liquid, while a mass ratio of about 1:19 with 22K random AOC

is a solid. The mass ratio may be at least about 1:4, about 1:3, or about 1:2;
the mass ratio may also be not more than about 2:1, about 3:1, or about 4:1. The compositions may be further described by intermediate ranges using the afore-mentioned upper and-lower limits.
s The mechanical properties of most polymers need to be adjusted by the inclusion of plasiticizers to make them suited to their intended use.
Plasticizers are used to make the polymer softer, more malleable or ductile, and less brittle, and must be miscible with the polymer to fulfill this function. Most plasticizers are small molecules, which by their nature, are often toxic or non-biocompatible 1o and easily released from the polymer. A polymeric plasticizes would be very valuable for many applications, especially one that was biocompatible, not toxic, not metabolized, and rapidly eliminated. Polymeric plasticizers for solid alkylene oxide polymers and copolymers have not previously been described.
Our extensive efforts to find a suitable biocompatible material that could be 15 used as a softener or plasticizes eventually led to the identification of a specific molecular weight range of random AOC which forms compatible or miscible blends (i.e., polymer alloys) with block AOC and AOH (see Tables). The finding that a liquid random AOC could be used in combination with a solid non-random PAO to form a novel polymer alloy with commercial utility was 2o unanticipated and has not, to our knowledge, previously been described.
Polymer alloys can be made with handling characteristics that range from a grease-like consistency to a hard wax. The different levels of malleability and plasticity can be achieved largely by altering the choice of components and their proportions as outlined in the Examples and Tables. The various other 25 embodiments are made in a similar manner. The solid AOH or block AOC
copolymer component is normally not dissolved by the liquid random AOC
component at room temperature. A polymer alloy can be made, however, as follows: The solid component is brought to its molten state by the application of heat. The random AOC component is heated to the same temperature, and the so two components are thoroughly mixed by stirring in the molten state. Upon cooling, the AOC alloy is formed. Altering the cooling rate can also be used to adjust the handling characteristics and structure of the AOC alloy.

A non-flowable composition can be made with a relatively small amount of the solid block AOC component. As an example, an alloy containing 2 parts by weight of the solid poloxamer 188 to 98 parts of the liquid 22K random AOC
does not flow at room temperature (see Tables). On the other hand, a hydrogel made from poloxamer 188 and water would require 30% of the solid to form a non-flowable gel at 37°C, but would still flow at lower temperatures.
The compositions may alternatively be formulated in solid or liquid form (e.g., milling, agitating, kneading, or stirring), but heating of the composition is preferred to achieve uniformity with solid or viscous forms. The composition 1o may be sterilized by standard techniques such as autoclaving or irradiation. It may be molded by hand; applied with a brush, flat or shaped rod, or syringe;
formed into a bar or stick; or implanted/placed in the body. A device may be coated or a bioactive agent mixed with excipient. Malleability, thermoplasticity, and viscosity may be measured by methods known in the art. Similarly, bio-compatibility and non-toxicity may be assayed by methods known in the art.
In one preferred embodiment, the composition is made by mixing a 1:1 ratio by weight mixture of a block AOC that is a solid at room temperature, such as poloxamer 188, with a random AOC, such as 22K random AOC, that is a liquid at room temperature. However, a range of physical properties for the 2o AOC alloy can be created depending on their intended use (see Tables).
In its anhydrous state, poloxamer 407 (PLURONIC~ F127) is a hard solid, and it is available as a gritty powder or in flake form and as such is not very useful. Adding even small amounts of the 22K random AOC softens the hard material, producing a homogeneous wax or soap-like material with improved handling characteristics, but with the surfactant and other properties similar to those of the original poloxamer 407. With increasing concentrations of the random AOC, the composition becomes more malleable.
Conversely, 22K random AOC is a flowable, viscous liquid at room temperature. By addition of as little as 2% (wlw) of poloxamer 188, a polymer 3o alloy is formed which handles like a greasy solid and does not flow at room temperature.

It is anticipated that other synthetic AOC will be developed and become commercially available. It may be feasible, for example, to make compounds containing AO chains that do not fall clearly into the scope of the claims. It is conceivable that a high molecular weight compound that is a liquid at room s temperature could be made that would fall outside the strict classification of a random AOC, or that a AOC essentially solid compound may not be strictly composed of blocks. It is entirely conceivable that a PAO copolymer could be made to contain sections of a block copolymer and a random copolymer. Such equivalents should be included within the scope of protection.
MEDICAL UTILITIES
Some embodiments relate to an adhesive material that can be used in orthopedic surgery, dentistry, reconstruction, spinal and craniofacial surgery, and other surgical applications because of its improved properties. Numerous uses include bone hemostasis agent or as an adhesive agent that can, for example, facilitate the adherence of a screw to the blade of a screwdriver. In one preferred embodiment, a polymer alloy is made using a 1:1 ratio of NF
grade poloxamer 407 (PLURONIC~ F127NF) and 2260 random AOC. The handling characteristics of this formulation make it especially useful as a bone 2o hemostasis agent, as the sticky, cohesive wax adheres well to bone, even when the surface of the bone is wet. In contrast to the prior art, preferred embodiments provide a biocompatible, substantially non-toxic, stable (i.e., non-metabolizable and readily eliminated) polymer alloy with superior handling characteristics.
Porous implant materials are useful for the repair or reconstruction of the bony skeleton. Implants can be used to fill bony defects, or they can be to augment or replace bone or cartilage in humans or in animals. Porous implants with a pore size of 60 microns or greater exhibit tissue ingrowth into their pores.
Collagen is deposited within the pores and forms a highly static complex, which so is resistant to infection and exposure. For a porous composition to be effective as an implant material, it must fulfill four criteria: (1 ) biocompatibility, (2) the pores must be large enough to allow for tissue ingrowth, (3) the pores must interconnect, and (4) the structure of the implant must be both permanent and rigid enough to maintain the porous framework under conditions encountered at the implanted site. To be useful, the material must also be sufficiently easy to use in a clinical setting. It is also desirable for the material to be non-toxic, have a relatively long shelf life, be relatively economic, and have good handling characteristics. There is a need to improvement the handling characteristic and to add a resorbable composition to fill or cover the pores. Filling or covering the pores would allow the implant to glide through tissue planes and would keep debris from entering the implant.
io Therefore, a further object is to create a porous implant whose pores are filled or covered with a resorbable substance.
Porous implants used in humans and animals are made by sintering solid particles such as polyethylene, PMMA, or titanium; or they are adapted from naturally substances such as coral in the case of porous coralline 15 hydroxyapatite. Polyethylene, a biologically inert material, has numerous applications in surgery. It is a straight-chain hydrocarbon synthesized by the polymerization of ethylene. Hydroxyapatite and tricalcium phosphate are similar in composition to the major mineral component of bone and may be resorbed or remodeled, depending on their formulation. Methacrylate- and silicone-2o containing particles are not preferred for use.
Placement of porous implants into one or more bone defects is a common surgical procedure. Implant materials that allow for bone to grow into the pores are considered to be osteoconductive. Implants that have a bioactive component that induce bone formation, such as implants made from a bone 25 removed from a different location, are considered to be osteoinductive. In the event that it is desirable that native bone eventually replaces the implant, material that can be remodeled by the body may be preferable. In certain clinical situations, such as a defect in the adult human cranium, the bone is not expected to grow, and a non-resorbable formulation is preferable. Studies have so shown that in the craniofacial skeleton, a number of commonly used solid implants cause bone resorption adjacent to the site of implantation. Porous implants may not have the same effect.

The majority of porous implants that allow for tissue in growth are grossly solid structures with a microporous structure. To be clinically useful, they often need to be sculpted by the surgeon into their desired form. The microporous structure of the implant can cause the implant to adhere to tissue, s much like a piece of VELCRO hook-and-loop fastener, making the implant placement difficult. Debris deposition into the pores is another undesirable drawback to the use of porous implants. To decrease the risk of bacterial infection, the implant may be soaked in an antibiotic solution prior to use.
An implant whose pores are filled with a biocompatible excipient would 1 o be an improvement over the implants in current clinical use. Temporarily filling those pores until such time as in growth of tissue occurs would eliminate the accumulation of debris within the implant and could decrease the incidence of bacterial infection. Temporarily filling the pores using an appropriate excipient would also improve its handling characteristics to make the implant more 15 lubricious and less damaging to tissue, thus allowing the implant to slide along tissue planes during surgical placement. The appropriate excipient could then also become adherent in the presence of body fluids and lessen the incidence of malpositioning that can occur after implant placement. The biocompatible excipient could also serve as a carrier for therapeutic products. For example, 2o chemical compounds could be released over time as the excipient is resorbed.
A preferred carrier or excipient should be biocompatible, non-toxic, non metabolizable, readily eliminated, relatively economic, and have good handling characteristics. The composition may allow an implant to be lubricious to glide along tissue planes, but it should also enable the implant to become adherent 25 to surrounding structures when its final position is attained. Cohesion may be used to temporarily hold tissue together until more permanent attachments may be made. An anhydrous formulation might increase the half-life of a biological agent and reduce the risk of contamination.
In a preferred embodiment, water-soluble bone wax is applied to the so surface of a porous implant, for example a coralline, porous hydroxyapatite implant, which would cause the implant to become slippery when in contact with tissue fluids, thus facilitating the placement of the implant by reducing the adherence of the surrounding soft tissue.
In another preferred embodiment, a porous implant can be made so that its pores are largely or completely filled with a resorbable polymer. This could s be achieved, for example, by placing a porous polyethylene implant into a molten polymer composition under a vacuum, and then allowing it to cool. The resulting implant would glide along tissue planes, it would remain flexible, and it would be resistant to having debris collect within its pores. Once implanted, vascular and soft tissue ingrowth into the pores of the implant could occur as 1 o the polymer alloy is resorbed.
The prior art teaches the use of random AOC as lubricants with a high affinity for metal surfaces. But random AOC are liquids which, like oils, will flow away from surfaces unless continuously replaced. To formulate a grease which will remain in place for lubricating bearings and the like, manufacturers of such 15 products will often combine an AOC or AO homopolymer base stock with an ionic soap, usually lithium, calcium, or sodium based. There is an unmet need for a non-flowable, non-ionic, non-corrosive, and completely water-soluble grease-like lubricant, particularly one that is biocompatible and suitable for use in medicine and surgery. In another embodiment, a water-soluble composition 2o is used as a non-flowable, non-corrosive, and water-soluble lubricant.
During surgery, lubrication of instruments or other devices is usually limited to physiological saline and the patient's own fluids. Use of lubricious substances derived from human or animal sources risks an immune response and the transmission of infectious agents. There is a need for a safe, biocom-25 patible, inexpensive carrier that could be used as a surgical lubricant that can be applied when needed. Such a lubricant could decrease tissue injury and/or improve the handling characteristics of devices as they are passed through tissue. Examples of injuries caused by surgical instruments are abrasive tissue burns caused by endoscopic instruments as they are moved along narrow 3o tissue planes. Surgical implants, such as those made from porous poly-ethylene, are especially difficult to pass along tissue planes, since soft tissue tends to adhere to these implants. Breast implants, especially those with a textured surface that are placed through small, remote incisions, can be very difficult to place without sufficient lubrication. Thus, the composition may be used as a carrier for devices (e.g., implants, instruments) to ease insertion.
In one embodiment, the AOC alloy can be used as a lubricant and/or protectant. For example, a polymer alloy made using a 1:19 ratio of NF grade poloxamer 407 (PLURONIC~ F127NF) and 22K random AOC could be applied to the surface of a steel surgical instrument, prior to the instrument being used in surgery. The polymer alloy would serve as a protectant, and would have the advantage over prior art in that it is not liquid, therefore it would not flow, nor 1o would it be absorbed by cloth that typically comes in contact with surgical instruments. It would have the added advantage of being completely water-soluble and non-toxic. Once used in surgery, in the presence of tissue fluids, the surface of the instrument would become lubricious, which would enhance the ability of the instrument to glide along tissue surfaces.
Another embodiment is an adhesive material comprised of a matrix (e.g., PEO, or a block AOC copolymer or a random AOC copolymer, or a combi-nation thereof) combined with a porous or solid filler for use in surgery.
In a number of clinical applications, it is advantageous to construct a porous structure by placing an aggregate of solid particles or granules that 2o become fixed in into their desired location by the in growth of soft tissue into the spaces between the particles. Allograft bone is a substitute source for solid particles. It is readily available and precludes the surgical complications and patient morbidity associated with autologous bone as noted above. Allograft bone may be considered a collagen fiber reinforced hydroxyapatite matrix 2s containing active bone morphogenic proteins (BMP) and can be provided in a sterile form. The mineral component may be removed from bone to form a demineralized bone matrix (DBM). Such ,DBM is naturally both osteoinductive and osteoconductive. Once surgically implanted, DBM is fully incorporated in the patient's tissue and it has been used in bone surgery to fill osseous defects.
3o DBM is usually available in a lyophilized or freeze-dried and sterile form to provide for extended shelf life. The DBM in this form is usually very coarse and dry, and is difficult to manipulate by the surgeon. It is known that DBM can be supplied in a matrix of low molecular weight solvents, but these are know to be toxic to the surrounding tissue, and they form a runny composition.
Therefore, one embodiment is to use the composition as a matrix for DBM. As an example, a composition containing a 1:2 mass ratio of poloxamer 5 407 (PLURONIC~ F127NF) and 22K random AOC can be used. The resultant DBM putty has superior handling characteristics and will adhere DBM to the intended site, it is non-toxic to surrounding tissue, and it contains no water that could inactivate the bone morphogenic proteins in the DBM.
Inorganic materials can also provide a matrix for new bone to grow at 1o the surgical site. These inorganic materials include hydroxyapatite obtained from sea coral or derived synthetically. Either form may be mixed with the patient's blood and/or bone marrow. Hydroxyapatite granules may be used as bone inlays or onlays. The granules can be mixed with microfibrillar collagen and blood from the patient. Although the mixture is termed a "paste" herein, it 15 may also be described as a gel, putty, or slurry depending on its handling characteristics.
Particles with sizes (i.e., the largest dimension) in the range from about microns to about 500 microns (or about 50 microns to about 150 microns) are desirable to minimize the possibility of particle migration by phagocytosis 2o and to facilitate injectability. Phagocytosis occurs where smaller particles on the order of 15 microns or less become engulfed by the cells and removed by the lymphatic system from the site where the augmentation material has been introduced into the tissues, generally by injection. At the lower end, particles greater than 15 microns (typically 35 microns or above) are too large to be 25 phagocytosed, and can be easily separated by known sizing techniques (e.g., filtration, gel exclusion, molecular sieving). For a population of substantially spherical particles, the diameter may range from about 35 microns to about 500 microns for at least the majority of the population. Thus, it is relatively simple to produce narrow or equivalent particle size ranges that are desirable for use.
3o Particles may comprise at least about 10% (v/v), at least about 25%
(v/v), not more than about 40% (v/v), not more than about 64% (v/v), or combinations thereof. The composition may be kneaded or otherwise worked to obtain a homogeneous distribution of particles within the composition. Such working is avoided, however, if a non-homogeneous distribution is desired and different compositions may even be laminated together.
As an example, polyethylene particles ranging in size from 50 to 300 microns are blended with a composition containing a 1:2 ratio of poloxamer 407 (PLURONIC~ F127NF) and 22K random AOC. The resultant polymer putty can be used to fill cranial defects. The matrix performs two important tasks: it forms a cohesive putty and serves to adhere the particles to the intended site of implantation. In this regard, the composition is superior to the prior art.
1o Excipients are biologically inactive substances that are associated with, often in combination, drugs, devices, and other therapeutic agents to make a therapeutic product. They may be classified by the functions) they perform as binders, disintegrants, fillers, diluents, suspending agents, dispersing agents, lubricants, flow enhancers, softeners, plasticizers, and coatings. Although biolo-gically inert, they may be critical and essential components of a therapeutic product. They might be used to reduce lability of a bioactive agent, enhance bioavailability, and/or control the location and rate of release of the bioactive agent. They also may be required to deliver a pharmaceutical formulation by a desired route, whether oral, parenteral, enteral, or topical and, if appropriate, to 2o enhance the appearance and palatability of the product. In many therapeutic products, excipients make up the bulk of the total dosage form. The excipient can be sterilized prior to formulation by autoclaving or irradiation, or the formulation may be sterilized as part of its production. In addition, a vehicle may be included in the therapeutic product. It may be water, another aqueous solution with buffer and/or physiological salts, non-aqueous solution, emulsion, or suspension. The device may be a filler, anchor, catheter, implant, plate, prosthesis, screw, suture, surgical instrument, or the like; it may be made from bone (e.g., chips or powder) or a derivative thereof (e.g., demineralized bone), ceramic (e.g., calcium salt especially hydroxyapatite), glass, polyethylene, or 3o metal (e.g., stainless steel, titanium). The drug may be a bone growth factor or morphogenic protein, hormone, other protein, nucleic acid (e.g., DNA, RNA, analogs or mixtures thereof), analgesic or anesthetic, antibiotic, antiseptic, narcotic, steroidal or nonsteroidal anti-inflammatory agent, or the like.
The compositions are also well suited as carriers or excipients for delivery of bioactive agents, medical/surgical devices (e.g., implants and instruments), and other therapeutic (e.g., non-polymeric) products. Articles may be coated with carrier or chemicals may be mixed with excipient. Sterilization may be performed in an autoclave or by irradiation for use in vivo.
Bone morphogenic proteins (BMP) and TGF-beta are two examples of bioactive substances. Other differentiation factors, stem cell factors, antibiotics, 1o antibodies, antigens, chemotherapeutics, cytokines/chemokines, enzymes and their substrates (e.g., activators, inhibitors, or reactants), receptors (especially secreted forms and mimetics thereof) or their ligands (e.g., agonists or anta-gonists), signaling molecules (e.g., mediators of a signal transduction pathway, agonists or antagonists thereof) may be formulated in a composition with the composition.
For use as a carrier or excipient, the attributes of being biocompatible, substantially non-toxic, simple to manufacture, and readily eliminated by a human or animal are important. In addition, the composition may solubilize hydrophobic compounds and thereby release them into solution. An anhydrous 2o formulation has the benefit of providing a stable excipient to those bioactive agents that are labile in an aqueous environment. Furthermore, if water is present, the composition serves to bind the water to make it unavailable to interact with the bioactive agent. Water-insoluble compounds may be incorpo-rated into a polymer composition, and then administered to a subject. There is no prior art known to have these attributes.
Examples of a carrier or excipient are (1 ) polymer alloy containing a 1:2 mass ratio of poloxamer 407 (PLURONIC~ F127NF) to 22K random AOC and (2) polymer alloy containing a 1:1 mass ratio of poloxamer 188 (PLURONIC~
F68NF) and 22K random AOC.
3o Certain vectors, such as viruses and infectious particles, likewise are in need of an excipient that is free of water. One embodiment is to provide an excipient for biological vectors that is biocompatible, substantially non-toxic, and may be formulated to contain no water. Such an excipient has utility in delivering vectors to cells, tissue, organs, animals, and plants.
Joints of some surgical instruments (e.g., scissors and clamps) typically need to be cleaned and the joints need lubrication. Such instruments can be s dipped in instrument milk prior to their use in surgery. Thus, in addition to use as a detergent, the composition may be used as a lubricant. The effectiveness of a composition as instrument milk may be enhanced because of its biocom-patibility, flowability, substantial non-toxicity, and water solubility.
As described above, a composition may be used as excipient for drug 1 o delivery or in the manufacture of other bioactive agent-containing compositions to deliver such compounds to a subject though a variety of routes, including percutaneous, enteric, intranasal or respiratory, topical, and through mucous membranes (e.g., rectum). When ingested orally in sufficient quantity, the composition may have biological activity of its own due to the ability to draw 15 water into the gastrointestinal tract and act as a laxative.
Open wounds, particularly those that are infected or have a tendency to seep fluid, continue to be a difficult management problem for health care providers. The aim of wound care management in these situations include keeping the wound moist, thus optimizing the conditions for the wound to heal;
2o removing excess fluid and debris from the wound; and minimizing or treating infections. It would be advantageous for a component of the wound dressing to remain moist, have the ability to remove or absorb excess fluid, and be formulated to include an antimicrobial agent. Thus, one embodiment provides such a substance for wound care.
25 There are a variety of topical formulations encompassing creams, gels, and ointments, including sun blocks and wound dressings. There is an unmet need for a lubricious component which absorbs water and is thus beneficial in treating seeping wounds and stasis ulcers. The composition may be packaged in a bottle or tube, applied to the wound, and then optionally covered by a 30 occlusive or non-occlusive dressing. Alternatively, it may be prepackaged with the dressing under aseptic conditions.

Therefore, in some embodiments, the composition may be used as a laxative or wound dressing.
NONMEDICAL UTILITIES
Wax is an organic, plastic-like substance that is solid at 25°C
and melts to a liquid when heated. Because wax is plastic in nature, it deforms under pressure without the application of heat. The term "wax" is applied to a large number of chemically different compounds, and it has come to include compounds that are soluble in water. These waxes are said to have the 1 o properties of aqueous dispersion. U.S. Patent 6,554,052 teaches the use of a water-soluble wax to decease the amount of precious metal in the production of jewelry and its utility in the 'lost-wax' casting process. There is a need for improvement in the handling characteristics and the ease of manufacture of water-soluble waxes.
15 In one embodiment, the composition is used as a wax.
There is a need to formulate crayons and pastels to be non-toxic and washable with water. U.S. Patent 4,978,390 teaches a composition in the form of a crayon or marking pencil lead which is washable from fabrics, wallpaper and painted surfaces. A preferred embodiment of the composition contains an 2o epoxide derivative of a polyethylene glycol) resin. Such a composition has the disadvantage of leaving residue after the application of water. There is a need for a simple, inexpensive, substantially non-toxic, water-soluble crayon.
Appropriate compositions (e.g., a polymer alloy of about three parts by weight of poloxamer 338 and one part by weight of 22K random AOC) produce 25 a medium-hard wax that is not brittle and which can be rubbed onto a surface such as paper, without flaking or fracturing, like a regular wax crayon. A
wide range of harmless dyes can be used to color the composition, including those presently used to color the regular types of children's wax crayons, simply by mixing with the molten polymer mixture prior to casting the material into an 3o appropriately-shaped crayon mold. The crayon thus formed is made from only two inexpensive components plus dye, is non-toxic, and has the utility of a regular crayon for drawing but is fully water soluble. When added as a fine powder to the molten composition, many hydrophilic dyes (e.g., methylene blue) are dispersed but not dissolved. Crayons formulated in this way can have a pale, slightly mottled appearance. In use, these crayons only faintly mark the paper. However, since the crayon wax is water soluble, subsequent application 5 of a small quantity of water to the paper results in the development of bright, saturated colors often quite different from the apparent color of the crayon used. Thus, these compositions have utility as novel art materials. A further obvious benefit of the water-soluble crayon is the simplicity of clean-up if the crayon is misused. Washable dyes and other colorants are used as pigment.
1o In another embodiment, the composition is used to as a carrier for a color pigment that could be used in the manufacture of washable crayons.
Poloxamers and other detergents have been used to sterilize surfaces and materials. Such agents are usually in powder or flake form. There is a need for a non-ionic soap, detergent, or stain remover which has the utility of 15 poloxamers, including the ability to perform in solutions with a high mineral content (e.g., hard water) or solutions of high salinity (e.g., such as brackish water or seawater), and can be provided in an advantageous physical form with improved handling characteristics, such as a solid bar or rub-on stick. Here, the composition provides the surface active functionality of a non-ionic detergent in 2o a convenient, easy to use form.
The surfactant properties of the composition are of benefit when a non-ionic cleanser or stain remover is needed. Such a cleanser is of benefit in that it is environmentally safe, does not leave soap scum, and will perform in hard water and saltwater environments. As an example, an alloy of about of 60% by 25 weight of poloxamer 188 and 40% by weight of 22K random AOC can be melted and cast into a bar form, preferably similar to the shape of a standard bar of soap. The formulation can be used as a cleanser bar, and has an appearance very similar to glycerin soap, which can be further enhanced by including other cleansing agents, boosters, colorants, fragrances, and so moisturizers in the formulation if so desired. The main value of this embodiment is that the non-ionic surfactant property of poloxamer 188, which in its regular form is a hard white granular material, can be applied to tasks for which it has not been previously used, such as hand washing, in a familiar, simple and convenient bar form. Other poloxamers or similar block copolymers can also be used in place of the poloxamer 188. The non-ionic soap bar is effective for use as a mechanic's hand cleaner for removing oily and greasy grime, will work with hard water without producing soap scum, and can be used in saltwater.
Aqueous release agents are used in applications such as molding.
There is a need for a non-toxic, non-corrosive, water-soluble, non-flowable, and inexpensive release agent that will adhere to a surface but will release on demand, such as when placed into an aqueous environment.
1o In one embodiment, a water-soluble composition is used as an aqueous release agent.
For use as a water-soluble, non-petroleum-based, synthetic lubricant, the composition can be formulated in in any number of different grades from a hard wax to a soft grease simply by varying the proportions of the components.
15 A blend of about 30% (wlw) of a random AOC, such as 22K random AOC, and about 70% block AOC, such as poloxamer 188, cast into a simple stick form (e.g., in a retractable tube) provides a medium-hard lubricant stick that can be rubbed on where needed or applied safely directly to moving surfaces, cutting tools (e.g., saw blades, drill bits, planing machines) or parts of machinery.
The 2o water-soluble, non-oily nature of the composition is useful to prevent damage or staining when machining delicate materials or wood, and simplifies clean up.
The composition has further advantages when used as a metal lubricant because the random AOC component is attracted to, and plates out on, hot metal surfaces. The non-corrosive properties are also a benefit for metal 2s working applications.
A medium blend of about 40% of 22K random AOC, about 60% of poloxamer 188 can be used in bar or stick form as a rub-on lubricant for the underside of skis, snowboards and the like. For this application, the lack of toxicity, proven environmental safety, and non-corrosive nature of the 3o component materials are especially advantageous.
As an example of a grease, 95% to 98% of 22K random AOC and 2% to 5% of poloxamer 188 were blended to provide a stiff to soft semi-solid grease, which does not flow under gravity at room temperature. It is a useful grease alternative, especially for lubricating metal parts, because it is less labile than natural or petroleum-based oils, with the additional benefits of being water soluble, biocompatible, and substantially non-toxic. With very low amounts of block AOC, the blend may become a viscous, somewhat sticky, oily liquid which has utility as a lubricant.
Any lubricant composition can also be used as a carrier for other friction modifiers (TEFLON particles, colloids, etc.), including potentially useful friction modifiers that are not readily oil soluble.
EXAMPLES
The following examples more particularly describe the invention but are intended for illustrative purposes only, since modifications and variations will be apparent to those skilled in the art.
Example 1 - Characterization of Polymer Compositions Specific characterization of various embodiments can be ascertained by using various specialized techniques (e.g., high-sensitivity differential scanning calorimetry), which can be used to probe the precise nature of the alloy and the 2o interaction between the component molecules. In particular, the miscibility may be confirmed by alterations in the glass transition temperature (Tg) of the alloy relative to the Tg of the individual components, if the Tgs of the individual components are sufficiently different. However, such measurements on polymer mixtures can be very difficult to make and interpret, even by experts in the field. If good results are obtained they are often strictly limited to the precise composition, volume fraction and temperature at which the measurement was made and, even with the best theoretical analysis, these data may have little predictive value for other combinations of polymers, even with only slight differences in the molecular weight or structure. Thus, it proved more expedient 3o to screen the polymer blends by direct observation both macroscopically and microscopically, to determine which combinations provides the desired combination physical properties, and to determine whether the polymers are compatible or miscible on the microscopic scale, as follows.
Non-random AOH or AOC and random AOC were blended together in various proportions. Appropriate amounts (w/w) of each polymer were placed in a glass container to prepare 10 g of polymer mixture, and heated in a microwave for 60 to 90 seconds to melt the solid component (the time was varied as necessary for the polymer mixture to reach approx 80°C).
After thorough mixing, the samples were centrifuged at 500g for 2 minutes to eliminate any air bubbles. All samples had a water-clear appearance in the molten state at 80°C.
For macroscopic evaluation, the molten polymer blends were reheated to 80°C and cast into small bars by pouring into individual aluminum molds of 2 inch x 0.75 inch x 0.1 inch deep, and held at 4°C until fully set (less than 5 min).
The appearance and mechanical properties of each sample were evaluated visually and by hand molding in a manner simulating some of the intended applications of the polymer alloy. For the microscopic testing, 15,1 to 20,1 of the melt was pipetted onto a glass microscope slide on a thermostatically controlled hotplate. A coverslip was placed on top of the melt and slight pressure applied to cause the polymer blend to flow just to the edges of the 2o mm x 25 mm coverslip, to form a consistent thin layer. The slide was then removed from the hotplate and examined under the microscope. Copolymer spherulites or immiscible blends were photographed at 10X magnification. A
differential interference contrast system (crossed polarizers) was used to enhance the characteristic birefringence pattern (Maltese cross) displayed by spherulite crystals.
Three random copolymers were evaluated: a three-branched 22K g/mol random AOC (22K random AOC) with an EO:PO ratio of 1:1 (BASF Pluracol~
V-10); a linear 12K g/mol random AOC (12K random AOC) with an EO:PO ratio of 3:1 (Sigma-Aldrich #43,820-0), and a linear 3.9K g/mol random AOC (3.9K
so random AOC) with an EO:PO ratio of 1:1 (Dow UCON 50-HB-5100). The non-random copolymers were selected from a range of Pluronic~ block copolymers (F68, F88, F98, F108, F87, F127) and PEO (homopolymer) fractions of various molecular weights (about 1.SK, 2K, 3.5K, 5K, 7.5K, 12K, 20K, and 35K g/mol).
The macroscopic properties of the polymer combinations are described in the Tables, including both descriptive data and a semi-quantitative ranking for each property of interest, for which the 1:1 alloy of F68 and V-10 was used as a reference point. The data show the ranges of compatibility for different types and molecular masses of poloxamers and PEO molecules with each of the three random copolymers.
For the 22K random copolymer, macroscopically compatible blends 1o could be made with F68 (poloxamer 188) over a wide range of proportions, from 2% to 98%, with no evidence of incompatibility. The blends with a low proportion of F68 (2% and 5% in Tables) resembled clear, colorless greases, while the others were waxy solids, ranging from very soft to very hard, similar in appearance to other forms of wax (e.g., paraffin wax or candle wax). The handling properties of the alloys tracked the polymer proportions closely, with hardness increasing and malleability and ductility decreasing with increasing F68 content over the range from 2% to 80%. Mixtures of 22K random AOC with F88, F98, F108, F87 and F127 were also evaluated in selected proportions.
Relative to the F68 compositions, each of the other block copolymers conferred 2o slightly different and potentially useful characteristics to the composition. For example, a 50:50 mass ratio of F127 block copolymer to 22K random AOC
produces an alloy that was softer, more malleable, and tackier than a similar composition of F68 block copolymer and 22K random AOC, and had an attractive white opaque appearance while the F68 composition was clear.
Other differences are apparent from the data in the Tables.
The compatibility of PEO in combination with 22K random AOC was a function of the PEO molecular mass. Thus, macroscopically compatible blends were obtained for PEO of 1.5K g/mol to 5K g/mol, but 7.5K g/mol was minimally or not compatible and 12K g/mol PEO was clearly incompatible with the 22K
3o random AOC, as indicated by a grainy texture and lack of cohesion of the blend. The compatible PEO compositions were generally similar to the block copolymer compositions, but tended to be softer and more ductile, and to have a different "feel", i.e., more oily to the touch and a gum-like tackiness.
The 12K random AOC random copolymer also formed alloys with the same block copolymers and PEO homopolymers (2K, 3.5K, and 5K) and was 5 incompatible with PEO samples of 12K and above. The 12K random AOC
alloys were almost identical in terms of mechanical properties and appearance with the equivalent 22K random AOC compositions. In contrast, the lower molecular weight random EO:PO copolymer, 3.9K random AOC, was not compatible with any of the block copolymers or homopolymers evaluated in the io study: although apparently completely miscible at 80°C, the blended polymers separated on cooling, forming a two-phase system of hard crystalline grains of the non-random polymer in a sticky or liquid carrier (predominantly the 3.9K
random AOC). These results indicate that higher molecular weight random AOC are necessary to form compatible blends with block AOC and PEO: the 15 threshold presumably lies between about 4K g/mol and about 12K g/mol.
Although most of the AOC polymer combinations formed macroscopi-cally homogeneous materials, the microscopic studies were necessary to provide confirmation of the compatibility of the polymer phases. Figure 1 shows low power (125x) views of alloys of 22K random AOC and F68, in proportions 2o from 2% (w/w) to 98% (w/w) after cooling. Looking first at the 20% (w/w) to 60% (w/w) samples, each image is very similar, with each spherulite crystal extending through the material to meet adjacent spherulites along very precise boundaries without any gaps or spaces. From 2% (w/w) to 10% (w/w) F68 blends, the spherulites are less distinct due to the lower amount of the crystal-25 line F68, but it is apparent that the size of the spherulites is the same and again, there are no gaps or other defects. Above 60% (w/w) F68, there is an increase in the spherulite size, and lines (dark under the microscope) appear between the region between the spherulites. Observation of the polymer blend while cooling revealed that these lines are in fact negative defects that appear so suddenly in the liquid phase between the advancing spherulite boundaries, presumably due to the sudden nucleation of a gas bubble under the negative pressure resulting from the contraction of the material. These bubble defects appear to be the cause of the increased whiteness and opacity of the alloys with increasing F68 content. The regularity of the spherulite structures and the absence of 22K random AOC-filled spaces between the spherulites indicates that the material is effectively a single phase, with the two polymers completely and intimately associated with each other at least on the micrometer level.
Figure 2 shows a 1:1 mass ratio of random copolymer and non-random polymer. Figs. 2A-2B are from compatible alloys - note the even spherulite pattern, and the absence of any defects. Figs. 2C-2E are examples of incompatible and immiscible compositions. Several distinct phases are seen -1o some large spherulite crystal domains of the PEO interspersed with large clear globular regions of the random copolymer, within which are additional smaller droplets of PEO which have crystallized into shapes corresponding to the interface of the phase-separated droplet.
Thus, we have defined the range of compatibility for combinations of s random and non-random alkylene oxide polymers, making possible the creation of polymer compositions with a range of very useful material properties. The results further indicate how to select the precise types, molecular masses, and proportions of the component polymers to tailor the material properties of the composition to satisfy the desired specifications. The discovery of compatible 2o combinations of these types of polymers, and identification of appropriate molecular weight ranges for the component polymers is novel and unexpected, and is not taught by any of the prior art.
Example 2 - Polymer Composition for Bone Hemostasis 2s A preferred composition with utility as a bone hemostasis agent may be produced in the following manner: Equal quantities by weight of NF grade poloxamer 188 (PLURONIC~ F68NF) and 22K random AOC are sealed in a heat-resistant glass container and heated to a temperature of 80°C in an oven.
The contents of the flask is stirred for a period of 8 hours at 80°C.
The liquid 3o composition is allowed to remain undisturbed for another 16 hours at 80°C to allow air bubbles to escape from within the liquid. The liquid is then dispensed directly into TEFLON coated metal molds maintained at a temperature of 80°C.

The molds are cooled to 4°C for 15 minutes. The solid polymer composition is removed and placed into individual foil packets lined with a polyethylene coating. These packets are then placed into pouched appropriate for packaging sterile implantable devices. The product is sterilized using an appropriate dose of plasma radiation.
A study was performed comparing the long-term effects of AOC wax and commercially available beeswax in paired cranial defects in the adult rat. Two defects 4 mm in diameter were hand cut using a dental drill through the parietal bones on either side of the midline in 10 Sprague-Dawley rats. The materials 1o used were in the shape of disks 4 mm in diameter and 1.0 mm thick, and were either AOC wax comprised of equal quantities by weight of NF-grade poloxamer 188 (PLURONIC~ F68NF) and 22K random AOC, or beeswax (Bonewax, Ethicon, Inc.). Both materials were implanted into each rat. At surgery, the two materials exhibited no difference in their handling characteristics and hemostatic effects. Animals were sacrificed at 7 days, 30 days, 60 days, and 90 days. On gross inspection, the beeswax remained present in each animal and there was no remaining AOC wax. There were no visible ill effects of the AOC wax. After formalin fixation, plain radiographs (16 inch distance, 50 kV for 0.1 sec) were obtained. No ill effects of the AOC wax on bone healing could be seen upon examination of the radiographic images.
The bones specimens were then decalcified in 5% acetic acid for 7 days, embedded in paraffin wax and sectioned for hematoxylin and eosin (H & E) staining. Upon microscopic examination of the specimens, there was no evidence of deleterious effects of the AOC wax on bone healing, the local tissue or the underlying brain.
Example 3 - Non-Toxicity of Polymer Composition The biocompatibility of the composition was demonstrated by assessing intracutaneous reactivity, systemic toxicity, cytotoxicity, hemolysis, mutageni-3o city, and the potential for chromosomal aberration. The composition used for all tests was composed of equal quantities by weight of NF-grade poloxamer 188 (PLURONIC~ F68NF) and 22K random AOC.

The composition was evaluated for intracutaneous reactivity to test for potential irritation and sensitization. A 0.2 ml dose of the material was injected by the intracutaneous route into five separate sites on the backs of rabbits, along with controls. Observations for erythema and edema were conducted at 24, 48, and 72 hours after injection showed no evidence of irritation. The primary irritation index characterization for the composition was negligible.
The composition was evaluated for systemic toxicity in accordance to the guidelines of the United States Pharmacopoeia and the International Organization for Standardization (ISO) 10993. A single 50 ml/kg body weight 1 o dose of the material was injected into mice by the intravenous route. The animals were observed at timed intervals for 7 days without any evidence of systemic toxicity.
Cytotoxicity was assessed using an in vitro biocompatibility study based on ISO 10993. A solution was prepared supplemented with 5% serum and 2%
~5 antibiotics, placed over confluent monolayers of L-929 mouse fibroblast cells propagated in 5% C02, and incubated at 37°C in the presence of 5% C02 for 48 hours. The monolayers were examined microscopically at 48 hours and showed no evidence of a change in cell morphology, cell lysis, or cell toxicity.
The composition was also tested in vitro to see if it would cause hemo-20 lysis (lysis of red blood cells) when in contact with human red blood cells. The material was incubated in a solution of human red blood cells for 4 hours.
After incubation, no released hemoglobin was detected, which indicated an absence of hemolysis.
The potential carcinogenicity of the composition was ascertained using a 25 bacterial reverse mutation study in which mutagenic potential was assessed in histidine-dependent strains of bacteria. The genetically altered S.
typhimurium strains TA98, TA100, TA1535, and TA1537 cannot grow in the absence of histidine unless specific mutations occur. The presence of mutagens increases the rates of these mutations. With the addition of 5 mg of the material per 3o bacterial culture plate, there was no evidence of cytotoxicity or mutagenicity.
Further evaluation of potential carcinogenicity was performed by in vitro testing of chromosomal aberration in mammalian cell culture. The assay used Chinese hamster ovary cells to detect changes in chromosomal structure. The chromosomes were observed in metaphase which had been stained with Giemsa stain. No evidence of chromosomal aberration was detected.
Example 4 - Hydroxyapatite Bone Filler Synthesis A preferred composition blended with hydroxyapatite particles with utility as a bone filler may be produced in the following manner: A ratio of one part by weight of PLURONIC~ F68NF (poloxamer 188) and two parts by weight of 22K
random AOC (PLURACOL~ V-10) are sealed in a heat-resistant glass 1o container and heated to a temperature of 80°C in an oven. The contents of the flask is stirred for a period of 8 hours at 80°C. A ratio of two parts by volume of the liquid polymer is blended with three parts of hydroxyapatite particles ranging in size from 50 to 300 microns. The composition is maintained at under a vacuum another 16 hours at 80°C to allow air bubbles to escape from within ~5 the formulation. The composition is then dispensed directly into 1 cc syringes and cooled to a temperature of 4°C. After 15 minutes at 4°C, the syringes are placed into individual foil packets lined with a polyethylene coating. The product is sterilized using an appropriate dose of plasma radiation.
2o Example 5 - Polyethylene Bone Filler Synthesis A preferred composition blended with high density polyethylene particles with utility as a bone filler may be produced in the following manner: A ratio of one part by weight of F68NF (poloxamer 188) and two parts by weight of 22K
random AOC are sealed in a heat-resistant glass container and heated to a 25 temperature of 80°C in an oven. The contents of the flask are stirred for a period of 8 hours at 80°C. The liquid polymer is then blended with an equal mass of high-density polyethylene particles ranging in size from 50 to 300 microns. The composition is maintained under reduced pressure for another 16 hours at 80°C to allow air bubbles to escape from within the formulation. The 3o composition is then dispensed directly into 1 cc syringes and cooled to a tempe-rature of 4°C. After 15 minutes at 4°C, the syringes are placed into individual foil packets lined with a polyethylene coating. The product is sterilized by irradiation.
Example 6 - Demineralized Bone Matrix Delivery Under sterile conditions, demineralized bone matrix (DBM) particles (200 to 500 microns in size) were prepared. DBM was blended with the composition (2:3) so that each gram of the blend would contain 5 mg of DBM. A control of DBM blended in a 5% gelatin solution was used. Subclones of mouse myoblast cells were used to determine the bone making (osteogenesis) potential of the io blends. This was achieved by assaying the alkylene phosphatase activity of the cells. The amount of osteogenic activity, as measured by alkaline phosphatase activity, was the same in both groups. The results of this study suggest that the composition is a suitable excipient for DBM.
15 Example 7 - Formulation for Drug Delivery The hydrophobic red dye Sudan IV was chosen as a surrogate for . hydrophobic pharmaceutical agents. This dye is widely used as a lipid stain.
It was combined with two different block AOC / random AOC composition, together with appropriate controls, in order to evaluate the ability of the 2o composition to disperse the hydrophobic dye into an aqueous environment.
Dye was blended with the composition in two different ways: (1 ) Melt:
the composition was heated to 80°C, 5 mg of dye per gram of wax was added and the molten mixture stirred until the dye was fully dissolved. The wax was then allowed to cool to room temperature. (2) Mix: because some drugs may be 25 thermally labile, the dye (5 mg/g) and wax were kneaded together at room temperature until they gave a uniformly colored wax. The waxes evaluated were: (A) a 1:1 blend of poloxamer 188 and 22K random AOC; (B) a 1:1 blend of poloxamer 407 and 22K random AOC; (C) pure 22K random AOC. Controls were (D) beeswax and (E) Brij 700 (a PEO-stearate surfactant not suitable for so parenteral use). The dye (5 mg/g) was added to (C), (D) and (E) by melting, as described above. 0.25 g of either A or B was added to 40 ml deionized water and allowed to dissolve completely, after which 12.5 mg of dye was added to these two beakers (AO and BO) and to a third beaker (FO) containing 40 ml of deionised water. Immediately afterwards, 0.25 g of each of A1, A2, B1, B2, C1, D1, and E1 was then added to 40 ml of deionized water in a 50 ml beaker. All of the beakers were then stirred gently for 2 hours. Taking a stronger red color s to indicate a better release of the dye, the results ranked as follows:
E1: Bright red solution with very few dye particles remaining.

B1: Red solution with a few dye particles remaining.

A1: Deep pink solution with a few dye particles remaining.

B2: Dirty red solution with dye particles remaining in suspension.

o A2: Dirty pink solution with dye particles remaining in suspension.

C1: Pale red solution with dye particles in suspension.

B0: Very pale green solution with dye particles at the bottom of the flask.

A0: Very pale green solution with dye particles loosely aggregating at the air/water interface.
15 F0: Extremely pale green solution, tightly aggregated dye particles at the air/water interface.
D1: Clear solution with the floating colored wax showing no change.
The dye was almost completely insoluble in water or solutions of either A
or B, and was not released from the beeswax, but was dispersed readily into 2o solution when fully incorporated into either composition to an extent approach-ing that of Brij 700, a strong and non-biocompatible surfactant. A significant proportion of the dye was also dispersed after mechanical mixing of the solid dye (coarse powder/crystalline form). These results clearly illustrate the ability of biocompatible compositions to effectively release a hydrophobic material 25 from an anhydrous form into an aqueous environment.
Other bioactive agents (e.g., carbohydrates, lipids, natural products and synthetic analogs thereof, nucleic acids, small molecules synthesized by man, proteins, antibiotics, antibodies, antigens, chemotherapeutics, imaging and contrast agents, radiotherapeutics, receptors or their ligands) may be used.
so The depot effects, if any, of the composition may also be assayed to determine whether there is any enhancement of biological activity.

Example 8 - Water-Soluble Crayon A preferred composition was blended with a dye to formulate a water-soluble crayon in the following manner: A ratio of three parts by weight of poloxamer 338 and one part by weight of PLURACOL~ V-10 was sealed in a heat-resistant glass container and heated to a temperature of 80°C in an oven.
Dye was added at a concentration of 5 mg per gram of polymer and stirred until it dissolved. The liquid composition was then allowed to remain undisturbed for 16 hours at 80°C to allow air bubbles to escape from within the liquid.
The crayon was formed by pouring the liquid composition into molds and cooling to io 4°C for 15 minutes.
Example 9 - Biocompatible Cleanser The usefulness of the composition as a detergent may be assessed. Its surfactant activity and ability to remove stains or contaminants from the surface Of a device or instrument can be compared to other detergents used in clinical settings. Viscous compositions may be used in situations where the cleanser is intended to adhere to the surface in need of deep cleansing; otherwise, non-viscous compositions may be used for quick washing and rinsing. The biocom-patibility of the compositions would be advantageous because of the ease with 2o which the cleaned device or instrument re-enters use in the clinic. This is an alternative to harsh detergent cleansers.
Example 10 - Non-Corrosive Lubricant The usefulness of the composition as a lubricant may be assessed. Its ,ability to make a medical device, surgical implant, or instrument slippery can be compared to other lubricants used in clinical settings. Compositions of varying viscosity (e.g., oil to grease) may be used depending on the situation. The biocompatibility of composition and its rapid elimination would be advantageous because of its safety.
Patents, patent applications, books, and other publications cited herein are incorporated by reference in their entirety.

In stating a numerical range, it should be understood that all values within the range are also described (e.g., one to ten also includes every integer value between one and ten as well as all intermediate ranges such as two to ten, one to five, and three to eight). The term "about" may refer to the statistical uncertainty associated with a measurement or the variability in a numerical quantity which a person skilled in the art would understand does not affect operation of the invention or its patentability.
All modifications and substitutions that come within the meaning of the claims and the range of their legal equivalents are to be embraced within their 1 o scope. A claim using the transition "comprising" allows the inclusion of other elements to be within the scope of the claim; the invention is also described by such claims using the transitional phrase "consisting essentially of" (i.e., allowing the inclusion of other elements to be within the scope of the claim if they do not materially affect operation of the invention) and the transition "consisting" (i.e., allowing only the elements listed in the claim other than impurities or inconsequential activities which are ordinarily associated with the invention) instead of the "comprising" term. Any of these three transitions can be used to claim the invention.
It should be understood that an element described in this specification 2o should not be construed as a limitation of the claimed invention unless it is explicitly recited in the claims. Thus, the granted claims are the basis for determining the scope of legal protection instead of a limitation from the specification which is read into the claims. In contradistinction, the prior art is explicitly excluded from the invention to the extent of specific embodiments that would anticipate the claimed invention or destroy novelty.
Moreover, no particular relationship between or among limitations of a claim is intended unless such relationship is explicitly recited in the claim (e.g., the arrangement of components in a product claim or order of steps in a method claim is not a limitation of the claim unless explicitly stated to be so). All so possible combinations and permutations of individual elements disclosed herein are considered to be aspects of the invention. Similarly, generalizations of the invention's description are considered to be part of the invention.

From the foregoing, it would be apparent to a person of skill in this art that the invention can be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments should be considered only as illustrative, not restrictive, because the scope of the legal protection provided for the invention will be indicated by the appended claims rather than by this specification.

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa~~

~ 0 ca 0 > 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 '~

. o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 c~c~c~ c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~c~~
o O U

U

L y ' (S$

+~'.~ ~ .C .C N N N N N .~ N N N O O N N O N N N O

d O O O O ~ C C C C ~ C C C C U C C C C C C C

O O O O a ,~ ~ O O O O O O O O O ~ O O O O O O O
~ ~ ~ ~
~

C1.~ N N
~ N
~~+'~.
N N N N
N
N
~
N
N
~
N
N~
N O O
N
~
N
N
fn fn N N
N

V _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ O ~ ~ ~ ~
Q ~
Q ~
Q ~
fl Q ~ N ~ N
Q
~
~ ~ L i L ~

.
.
.
.
.
.
.
_ _ L L L L O ~ hr 'C~ C~ .~ ~ ..Q ~ i .fl .fl .O .Q O
O ~ O -Q X X -Q c~3 CCS C~ ~ ~ ~ .O
N N N O E
O O O O O O O O O O O E ~ O E O
O O O O O O O O

N O O
N O
> > > > In .r + U U U U U U > U U U U fn fn U Cn U
.,.. .n... U U U U U U U U

r r r r N M M d- Ln 'd' V' d' 'd' r '~ ~ W t d' N d' U N d' M M '~i' ~ u7 ~ '~h d' 'd' '~t z ' a N

a U

a a a L

O U

O N O N N N N N N O N N O
.Q..
U U .' ..

_ Y O ~ 7 ~ ~ ~ O ~
L CT CT CT O' a' L ~ ~ LT L L L .~ .O .O L CT

N (CJ cL3 fCJ (~ fSS > O (Lf (~S c0 (a f~ f~ ~ to fCf (~ (Lf (~ f~ ~ ~ ~ fSS (LS (Lf 'aN N N N N ~ ~. O- Q- Q- O- N O Q. Q a. ~ O N ~ Q.

a UU-U-U -U-U~ UO0000 V V 00 O V U UU~~~ U00 L L : N _~ _~ _~ _~ ~ L L _N N L _N ~ L L : _~ ~ _~
_~

' J > > > > > U U tn ~ ~ ~ ~ ~ fn > U U ~ ~ U ~ In tO U
U c0 ~ ~ E ~ f4 S

r r r r r N M u7 Cfl CO I~ f~ M r N N ~ ~ N CO M N N N N dWt 'cY ~
Cfl CO

T
N

o 0 O

O
~
N~~ N
~
~
~
~~~~
' ~~N
'0 ~~~~
O' 0'~~~~
O

t C
C
a c O

f J
C
~
O
OLt 71t 71t d d ~

Z

O

a L YYYYYYYYY'SYY

O ~ O ~ ~ ~(7 ~I7 ~ ~ Ln O Ln N
~
M
' ()~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ O O ~ N r N M M M
C
M M M LI
f~ ~

O LL LL LL LL LL lL LL !L'tL LL Il LL LL LL LL LL Il r r IL r ~ ~ ~ ~ ~ O ~ ~ ~ O O
~~ ~

a -wwwwwwwWwwww ~~a~o_o_o_ U

z o o m d o O
OtnN~~
'O
~~~ ~~
~~N
O

~
~~~
O

~
~
O
O'MN
~
~' ' N

O
C
r OL
I
I.
~o L
I~I
L
C

( c d O
d O

U

O

O

a YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY

O N N N N N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N

N N N N N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N

G

O

o a~
a~
o a~
a~
a~
a~
a~
a~ a~

_ _ _ _ _ _ _ _ _ _ aaaaaaaaaa~~~~~~~~~~~~
+. 0 0 0 0 0 0 0 0 0 0:

~ QaQQQQaaa~
>. o 0 0 0 0 0 0 0 0 0 ca ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 0 0 0 0 0 0 U U U U U U U U U U U
c c c c ~ c c ~ ~ c c V

d ~ o a~ o o a~ a~ a~ a~ a~ o a~
c c ~ c c ~ c c c c c +. ..r ..J +. ..-. +. -. .~. ,...
.. ..J ca ca cn ~ ~n a cn v~ ~n cn a ~n ~n u~
~n u~ a a a a a a a~ o a~ ~ a~ a~ a~ a~ ~ a~ a~ a~
a~ a~ ~ a~ ~ ~ ~ ~ a a X ~ ~ ..~Q ~ '~ ~ ~ ~ ~ ~ '~ (~ X
X X X p' ~

O E O O O O O O O O O O O O O O O
O O O .
-UWU+.UUUU.~.UUUUU.,rU+..,.'.,...,..G

U
d' N d' M ~h ~h d' d' M '~t d' '~t ~t d' M ~ M M M M O O

Z

a a '~ o o ~
p" v L L -a a L

a U U ~ ~ U

w w O O w ~ U

Q N L i 'O L L .C ~ i ~~ .~ ~ a' ~ ~

N
a c~ c~ ~ c~
a-~.~.c~.c.~~.c ~ a~ 0 3 n I a .
O ;~ ~ ~ O O
V

LL ~ O
J U U O U
~~o ~~~ o ~ ~ ~ O ~ ~ ~~~~a~~~ ~

L L L

N d' ~t .- M ~t CO dwt ~t c0 CO I~
I~ f~ I~ I~ f~ I~ I~ ~ L(7 o ~ ~ ~ N ~ ~ ~ ~ ~ ~ ~
~
~ ~ ~
~ ~
~ ~ ~
~

u l t t t Z

O

a YYYYYYY YYYYYY

GO 00 OJ i~ O ~ O ~ N O ~ ~ ~I? O
~ O In N

U M M M O O O N N M tt~ t~ T' N M o0 ~ nj ~rj ~j ~ r a ~~~'~~~~ooooooo;~~000000 ~

p ~ aa~~a.~a. a.a~a .a~

E- o v~ m O
a O ~ ooo~no~.c~oooo000000000000 () o tn Lf7 d' I~ LIB N Lf7 Ln Lf L
L

n Lf) O Lf7 In LIB In LO LI7 LO Ln LL~
In U

O

a YYYYYYYYYYYYYYYYYYYYYY

N N N N N N N N N N N N N N ~ O O
O O O O O
~

T T T T
T T T T T T T T T T M M M M M M M
C

~ ~ ~ > > ~ ~ ~ > > ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
~ ~ ~ ~ ~ ~ ~

0 0 0 0 0 0 o N

a~ a~ a~ o a~ a~ o n~ o a~ o a~ a~ o 0 o a~ a~ o 0 o a~ a~ a~ a~ a~ as a~ a~ o a~ a~ ,c ~ c ~ c c c c c c c c c c c c c c ~ c c c c c c ~
c c c c ~ c c ~

N N N N N p N ~ N N N ~ N N N N ~ N N N N N ~ N N
~ ~ ~ N N N ~ L

o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 H -E ~ E E ~ E E E E E E E E ~ E E ~ ~ E E E E E E E
E ~ E ~ E E E ~

s~
o ~~~~ ~

~
o ~~

o c o o ~~tt o o ~

o o c.
~.
~
c.
.
~.
.
c.
.
c.
~.
c.
~.
.
c .
~.
.
~.
.c.
~.
c.
o.

m N N N N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N r N

f0 !n tn 'Y .Y Y 1~ '-G ~ '-t fn In fn 'Y In fn fn ~ Y ''L fn L L L ~ ~ ~ ~ ~ ~ ~ L L L ~ L L L ~ ~ ~ L

Cf C ~ ~ ~ ,~ ~ ~ .CI .CI ~ .Q ~ ~ ~ ~ ~ ~ ~ ~ .~
.Q

a ~_U U V! fn l!J V7 fn fn (n ll7 Cn fn fn U7 fn In fn tn In Cn fn In Cn fn Cn tn CO fn ~ N N --"
'C; "a N
' 'p p ' ' ' ' ' ' ' ' ~
~
' ' ' ' ' o V p p O Q.
O
~
Q
D
~
p ~
p p Q Q
D Q Q
' ' ~
p p a ~
C
C C

C C C ~ C C f~ f~ - ~ ~ C C C f~ ~ ~ C C C C C C ~
C
f~ f~
N N L
N
' ' ' ' .
L N N N N N N N N
L
L
C C
L N N p C N
N ~ N N N N C C
fl tn tn Q
n n n o Q~~
Q~
~
~~
Q

.
.
.
.
.
.
.
.
Q..fl.Q~.Q.o.n tn tn.Q.fl~.n.fl~ tn .

-' a a Lt7 ~I7 ~ '~' 'd' C9 C''7 CO N N r r r CO C~ C~ N
C~ r d' d' d' M 'd' d' d' C~ C~'~ N N C~ d' r O ~ ~i O O O ~ ~ O

'a ~ m .c .o .o .o ~ ~ p ~ tn tn ~ ~ cn -o E E ~
' ~
' c ~
~ ca E E E E E as E O E E
o N O E E E E ca c fn ~ ~ ~ ~ ..C .C ..C > > ~ 7 ~ t ~ t4 ~ ~ ~ 7 ~

a '~ >, ~ ~ =o ~ ~ -o 'o >, >, ~ ~ ~ ~ ~a ~ >, .~.
.,... .,., -o >, ... +. Wo -o 'a ~ ~
c o ' o m 'anEE~~~E>
~E>c nEEEE~EEEEE>e nc nu n~
aW>c n<

a r N C~ d' ~ Ln CO CO f~ 00 O M ~ CO Cfl CO f~ CO O
d' d' d' l17 CO 'd' d' 1.I~ In f~ M I~ ~ O

a O
o O

~~~
~N
~
~'d ~
~~~~
~
O'~~~~~~
O' O
~
N~~N

t o L
C
C

OV

C
O
C
C
O
O
d Z

a s.YYYYYYYYYYYY

p ' Ln O Ln In In ~ ~ Lt7 In O Lf] N

00 00 00 00 of o0 00 00 00 of of 00 of 00 00 00 a~
o ~ f~ N r N M c9 M C~ t~ M CO In t~ r t0 CO O CO O O CO CO O CO O CO CO 00 O O O o0 ~~~~~~~~~~~~~~~~~rr~rOOOOOOOOOOO~
~~ ~

z a -~,wwwwwWwwww~

~a~aa.a.~o_~ad~

a o m~nooooo0000 0000000000000000000 Ln N
L
I
L
' ~
' 7 N r ~ f~ CO Ln Ln N 117 ~ In In 00 I
O
n n CO l.n d M N
~ O) ~ OJ f~ CO LI7 ~t C

U

O

a YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY

N N N N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N N

C

~n ~n ~n v~ m cn v~ m m 0 0 ~ o o ~ 0 0 0 0 0 ~ ~n ~n N
~ ~ ~ ~n ~n ~n cn o a~ ,~ o o ~ a~ a~ as a~ a~ ~ ,~
c ,5 c c c c c c ~
' ' ' ' ' ' c ~ o c ~ c c ~ ~ o ~ ~ y ~
~
~
~
~
~
~ y L ~ Q~ L ~ ~ ~ ~ ~ L L L L L L L
L L L L

O o - o o - o o O O O - _ N N r N N r N N N N N .- r O T T
T T T T T O

N

N ~ ~ N ~ N ~
'Y Y 1' .Y 1~ 1' .Y 'Y

L ~ L L L

.Q

' = vi vi u~ vi vi v~ ui vi ui vi ui V vi ui vi v~ a ~n cn N ~ a~
'~ 'O Q 'O 'O Q. 'a "O 'O 'd '~
'~ '~ 'a B. ~ ~ Q Q. ~ N ~

C tLS C C (Lf C C ~ C C ~ ~ C (Cl ~ ~ f~ (iS ~J cCS (LS

a ~ N o c N a~ c a~ a~ a~ a~ N a~ N
N ~ L Q c c Q Q.
Q~~n cn~~
n cn Q
fl n n~
n~~ ~n ~
n ~n~

J a .
.
.
.
.
.
.
.

a z M C~ N '~h Cr7 N d' d' d' C~ M C'~
C~ C~ N ,- Lf7 N N ~I7 Lf7 In ~ 'O 'D 'O 'a L L L L L

,~,r +J 4~ 4~

N E E E E ~ E E E ~ O O O O

d 7 ~ ~ 7 ~ ~ ~ ~ ~ In tO In fO
' ' ' ' ' ' ' ' ' ' ~ o ~ -o .,.~
o a a ~
~
~
~
~
~ .~ ~.
o .~, ... .... ~ ~

N N ~"' N L '~ '~ '~ N N N N N Q~
~'-' L L L L L L

O

f~ I~ 00 ~Y f~ 00 ~t ~t d' I~ CO
cfl e0 C4 I~ ~t c~ o0 00 M c~ ch o ~
~
~
~~~~
~
~
~
~
~
~
~~
~
~
~
~
~
O
N

t l t l L

lS
L
L
L
I
t L
ntL
7l nC
O

Z

a YO~N
YO~
O
YO

O I
I
NOtY t V o0 00 of p p O N N c'~ tCa is r N C~ 00 N ,- CV CM LI7 1~ T

a ~~~~~~~ooooooo~~000000 ~~ a~aa aa ~

..n-o ~~-a ~

~ , t= o in m o a V o ~~~~~~~~
~~
~~~~~
~~
~
~N~

t l l l d ' V

O

a YYYYYYYY!YYYYYYY'-~YYYYYY

N N N N N N N N N N N N N N O M
O O O O O O

T T T~ T T T T T T T T T T T M M
(Y~ (Y~ (Y~ M (Y~ (Y~

c o -'jpl!7 Ln Cfl In d- N r O O O O O O O N r r O O
LL7 N N r In lI7 N r O O

4l s a O c o z TOOOOOrNNNOOOOOONOOOT'; OOOO

C
C) z O

W Wit' M M N N N r O O O N M N N N O ~ M M M d' d' M M M N

_ H-c0 W

a 0. ' M M M M M N N N O O O N M M N M M M M M M d-~ ~t d' d' N N

D

V N

r N
d C o N N M M ~t ~.(7 tf7 ~ cfl ~ O O ~ ~ dmn ~
~t O N
.~,.~ ~t ~
V
~ ~ ~ CO

J ~ ~
C
c a Nlf~~ N

' O
~t~
~~~
~
~
~NM'd t ~~
~
~W~~
~
O' ~
f ~t t t L
L
C

C
f O

d Z

O

a L YYYYYYYY

O tn O W tn tn u7 tW n 00 00 0 ~ f~ N
~
V
'~

(~r C
M M M M C
C
O O O O O O O O O O O O O M O O O M

O LL LL I1 LL LL LL LL LL lL LL LL LL LL LL LL
LL LL ~j ~ LL ~ O
O
O O
O
O
O O

a ~
~
~
~
~
~
~
~

a.o..
~~~
a.

H V

O

O
~
O~N~~~

O
~
~
~~ W
O
Or ~
~
O
N
N~~~
O' ~
O' U
c t d r t L
Oll O
Ot C
f7 t O
C
J

d U

O

a YYYYYYYYYYYYYYYYYYYYYYYYYYYYY

N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N

N N N N N N N N N N N N N N N N N N N N N N
N N N N N N N

C

R

>

_ c s c x N o m w o N .- o ~ co o c~ co co cmn ~r o ~r ~r c~

O II

s Q r O

z Y

a~

O
O II

d r T; N N O O N O O N O '; ''; O r m m p ~ ~ ~ M ~ M C~ C'7 M 'o O s a~

U1 U 's '~
Y

W v .
= -II

F o0 a >

O .Q .c >
n ~ r M d' O N N O ~t N O d' d' '~f d' N .
~ II if ~ d' O

_ ~U

V II

~
N

II -p ~

il r C~ CI'7 r C'~ C~ r M C~ r C~ C~ f~ C'~
C~ O O O O

V ~ ~ ~Y o D t>~
V

.
U
N
~' N >.
E

LLI -. _ N
-ii ~ li ~
~
~

m ~ c.~ c M
ca t c~ s !~ C~ M Q7 N N O ~t N O 'ct tt d' d' N

O

Z ~ cn '~ d, .~
II r O

O O O O O O O O in O Ln O O O O O O O O O
O O O O O O O O ~ ~ - y, O tIWCd L~ L~ ~ CO N It7 IW.I7 ~ ~ tn >
Ln ~ l~ tf7 tI~ tI~ LO In tn LO t1~ Ln U ~

Lf7 ftf O r.
L

+:~ E a0 U

m o II o a II

Y~1YY YYYYYYY YYYYYY II NN

O Ln O tn N O ~ O Ln N O u7 In O in O tt~
N N C9 !r s ~
' O

C~ ~ t~ r a0 00 00 p p O N N c'~ ~ h~ _ r N CD of N .- CV c~ l(7 I p ' -' '-' O

O rTTOOOO00W.i. O
OOOOO c OOOOtiu.u.T
w ww' ' "

z a wwwwww -wwwwwww wwww --O ~ d d a n- a. 0. d d o- n. a. a a a. d a o-v O ~ ~ II
V
~ N ~
'O

m , N

Y
~

d M U O
' O
Q ~

o O O O O O O O tn O ~ O O O O O O O O O "- II ''~
O O O O O O O
Lf7 tc~
L
L
' n n fit I~ lf7 N ~l? ~ LO In LO Ln LO Ln LI~
Ln Ln In N Ln L(7 Lf7 In lI~

II r ~ r Q N m O 7.
YYYYYYYYYYYYYYYYYYYYYYYYYY C
~ O O O O O ~ m o~U,o_ N
O
' N N N N N N N N N N N N N N N N N N O ~
'I ,p ' I~ (Y~ (Y~ (Y~ (Y~ ( ~
N N N N r r T r r r r T r r r r r T (Y~
(Y~ ( U

lC O U il ~

II II p r O ~O 1 C

_ Q
~ :p ft1 N N

fi5 ~ (CS
'O .C

=~~QU

Claims (57)

1. A composition comprised of: (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s.
2. The composition of Claim 1, wherein said composition can adhere to bone, skin, or other body tissue.
3. The composition of Claim 1 or 2, wherein said composition is biocompatible and substantially non-toxic.
4. The composition of any one of Claims 1-3, wherein said composition is substantially non-metabolizable and readily eliminated in unmodified form.
5. The composition of any one of Claims 1-4, wherein said composition is water soluble but is in a substantially anhydrous form.
6. The composition of any one of Claims 1-5, wherein said composition is not formulated with water.
7. The composition of any one of Claims 1-6, wherein said composition has a consistency at 25°C of a viscous oil to a hard wax.
8. The composition of any one of Claims 1-7, wherein said other alkylene oxide(s) is propylene oxide and/or butylene oxide.
9. The composition of any one of Claims 1-8, wherein said composition is further blended with one or more additives selected from the group consisting of solid particles, other polymers, and color pigments.
10. The composition of any one of Claims 1-9, wherein said random copolymer has a molecular mass of at least 5 kg/mol.
11. The composition of any one of Claims 1-9, wherein said random copolymer has a molecular mass of at least 10 kg/mol.
12. The composition of any one of Claims 1-9, wherein said random copolymer has a molecular mass of at least 20 kg/mol.
13. The composition of any one of Claims 1-12, wherein said random copolymer has a molecular mass of not more than 25 kg/mol.
14. The composition of any one of Claims 1-12, wherein said random copolymer has a molecular mass of not more than 50 kg/mol.
15. The composition of any one of Claims 1-12, wherein said random copolymer has a molecular mass of not more than 200 kg/mol.
16. The composition of any one of Claims 1-15, wherein said random copolymer has a molecular mass from 1 kg/mol to 1000 kg/mol.
17. The composition of Claim 1, wherein said other alkylene oxide is propylene oxide, and said random copolymer has (i) a molecular mass from 15 kg/mol to 30 kg/mol and (ii) a mass ratio of the ethylene oxide to the propylene oxide from 25:75 to 75:25.
18. The composition of Claim 17, wherein said random copolymer has a molecular mass from 20 kg/mol to 25 kg/mol.
19. The composition of Claim 17 or 18, wherein said random copolymer has a mass ratio of the ethylene oxide to the propylene oxide from 40:60 to 60:40.
20. The composition of any one of Claims 1-19, wherein said non-random poly(alkylene oxide) is selected from the group consisting of poly(ethylene oxide), poly(propylene oxide), poloxamer, meroxapol, poloxamine, reverse poloxamine, and other block copolymers of ethylene oxide and propylene oxide.
21. The composition of any one of Claims 1-19, wherein said non-random poly(alkylene oxide) is a block copolymer.
22. The composition of Claim 21, wherein said block copolymer is a poloxamer selected from the group consisting of P108, P188, P238, P288, P338, P235, P237, P335, and P407.
23. The composition of Claim 21, wherein said block copolymer is a copolymer of ethylene oxide and propylene oxide.
24. The composition of Claim 23, wherein said block copolymer has a molecular mass from 10 kg/mol to 50 kg/mol.
25. The composition of Claim 23 or 24, wherein said block copolymer has a mass ratio of the ethylene oxide to the propylene oxide from 25:75 to 95:5.
26. The composition of Claim 21, wherein said block copolymer is a triblock copolymer of ethylene oxide and propylene oxide.
27. The composition of Claim 26, wherein said triblock copolymer has a molecular mass from 4 kg/mol to 20 kg/mol.
28. The composition of Claim 26 or 27, wherein said triblock copolymer has a mass ratio of the ethylene oxide to the propylene oxide from 25:75 to 95:5.
29. The composition of Claim 23, wherein said block copolymer has (i) a molecular mass from 6 kg/mol to 10 kg/mol and (ii) a mass ratio of the ethylene oxide to the propylene oxide from 60:40 to 90:10.
30. The composition of Claim 23, wherein said block copolymer has (i) a molecular mass from 10 kg/mol to 15 kg/mol and (ii) a mass ratio of the ethylene oxide to the propylene oxide from 60:40 to 90:10.
31. The composition of any one of Claims 1-19, wherein said non-random poly(alkylene oxide) is a homopolymer.
32. The composition of Claim 31, wherein said homopolymer has a molecular mass from 1 kg/mol to 20 kg/mol.
33. The composition of Claim 31, wherein said homopolymer has a molecular mass from 1 kg/mol to 10 kg/mol.
34. The composition of any one of Claims 31-33, wherein said homopolymer is poly(ethylene oxide).
35. A composition for use in medicine or surgery, which is comprised of (i) at least one bioactive agent, medical/surgical device, or other therapeutic product and (ii) the composition of any one of Claims 1-34.
36. Using or making the composition of any one of Claims 1-35.
37. A process for medically or surgically treating a subject, which comprises:
(a) providing the composition of any one of Claims 1-35, and (b) administering said composition to the subject.
38. The process according to Claim 37, wherein said composition is administered at least orally, parenterally, or topically to the subject.
39. The process according to Claim 37, wherein said composition is administered as a suppository to the subject's mucosa.
40. The process according to Claim 37, wherein said composition is administered during surgery by insertion into a body cavity or tissue of the subject.
41. The process according to any one of Claims 37-40, wherein said composition is used as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof for medical or surgical treatment of the subject.
42. A process of making a product, which comprises combining (a) at least one bioactive agent, medical/surgical device, or other therapeutic product with (b) the composition of any one of Claims 1-34.
43. A product made by the process according to Claim 42.
44. Use of the product of Claim 43 in a medical or surgical application.
45. A product useful for medicine or surgery, which comprises (i) particles suspended in (ii) the composition of any one of Claims 1-34.
46. The product of Claim 45, wherein said particles are from 10% by volume to 64% by volume.
47. The product of Claim 45 or 46, wherein said particles have a size from 35 microns to 500 microns.
48. The product of any one of Claims 45-47, wherein said particles are selected from the group consisting of bone chips or powder, demineralized bone, hydroxyapatite, polyethylene, and any combination thereof.
49. A process of making a product useful for medicine or surgery, which comprises suspending (a) particles in (b) a carrier comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s.
50. A product made by the process according to the process of Claim 49.
51. Use of the product of Claim 50 in a medical or surgical application.
52. A process of making a polymeric alloy composition, which comprises blending (a) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (b) at least one non-random polymer comprised of one or more poly(alkylene oxide)s.
53. A composition made by the process according to Claim 52.
54. Use of the composition of any one of Claims 1-34 and 53 in a'lost wax' casting process.
55. Use of the composition of any one of Claims 1-34 and 53 as cleansing bar or washable crayon.
56. Use of the composition of any one of Claims 1-34 and 53 as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof.
57. Use of the composition of any one of Claims 1-34 and 53 for hemostasis and/or tissue augmentation.
CA2515292A 2003-02-12 2004-02-12 Random and non-random alkylene oxide polymer alloy compositions Active CA2515292C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US44653403P true 2003-02-12 2003-02-12
US60/446,534 2003-02-12
PCT/US2004/004174 WO2004071452A2 (en) 2003-02-12 2004-02-12 Random and non-random alkylene oxide polymer alloy compositions

Publications (2)

Publication Number Publication Date
CA2515292A1 true CA2515292A1 (en) 2004-08-26
CA2515292C CA2515292C (en) 2015-09-29

Family

ID=32869526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2515292A Active CA2515292C (en) 2003-02-12 2004-02-12 Random and non-random alkylene oxide polymer alloy compositions

Country Status (9)

Country Link
US (6) US7553913B2 (en)
EP (2) EP1601326A4 (en)
JP (2) JP5508661B2 (en)
CN (1) CN1780596B (en)
AU (1) AU2004211991B2 (en)
CA (1) CA2515292C (en)
ES (1) ES2695401T3 (en)
TW (2) TWI367113B (en)
WO (2) WO2004071451A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
WO2004071451A2 (en) 2003-02-12 2004-08-26 Ceremed, Inc. Random alkylene oxide copolymers for medical and surgical utilities
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
JP3930896B1 (en) * 2005-12-28 2007-06-13 日本製紙株式会社 Functional composition, and wet paper method peelability enhancing USING
US7812098B2 (en) 2006-03-31 2010-10-12 Depuy Products, Inc. Bearing material of medical implant having reduced wear rate and method for reducing wear rate
US20070232762A1 (en) * 2006-03-31 2007-10-04 Depuy Products, Inc. Bearing material of medical implant having reduced wear rate and method for reducing wear rate
US8455000B2 (en) 2006-05-22 2013-06-04 Syncera Inc. Resorbable polymer compositions for use in medicine, dentistry, and surgery
WO2008089130A1 (en) 2007-01-17 2008-07-24 Dow Global Technologies Inc. Lubricant compositions and methods of making same
US8480651B2 (en) * 2007-08-02 2013-07-09 Covidien Lp Cannula system
AU2009232000B2 (en) * 2008-04-03 2014-12-11 Mallinckrodt Pharma Ip Trading D.A.C. Hemostatic microspheres
CN102066537B (en) * 2008-04-28 2013-08-14 陶氏环球技术公司 Polyalkylene glycol-based wind turbine lubricant compositions
CN102159163B (en) * 2008-07-14 2014-09-10 波利皮得有限公司 Sustained-release drug carrier composition
CN105126179B (en) * 2009-07-14 2018-09-25 波利皮得有限公司 Sustained release pharmaceutical carrier composition
UA107471C2 (en) * 2009-08-18 2015-01-12 Shell Int Research Of fuel and oil and its use
JP2013517050A (en) * 2010-01-13 2013-05-16 イノベイテイブ ヘルス テクノロジーズ エルエルシー Method and apparatus for bone distraction
US20110171596A1 (en) * 2010-01-14 2011-07-14 Clark David J Dental Wedge
JP5860409B2 (en) 2010-01-19 2016-02-16 ポリピッド リミテッド Sustained-release nucleic acid matrix composition
JP2013525299A (en) * 2010-04-16 2013-06-20 アパテック リミテッド Biological material
WO2011137231A1 (en) * 2010-04-29 2011-11-03 Warsaw Orthopedic, Inc. Flowable ceramic putty
JP5634754B2 (en) * 2010-06-03 2014-12-03 智広 梅田 Bone hemostatic composition
CN101864103B (en) * 2010-07-02 2012-08-08 天津市医疗器械厂 Mixture for intrauterine device
WO2012047290A1 (en) * 2010-10-05 2012-04-12 Theracell, Inc. & Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Oxygenated demineralized bone matrix for use in bone growth
DE102011016277B4 (en) 2011-04-06 2013-02-21 Heraeus Medical Gmbh Plastically deformable, biodegradable hemostatic agent and method for forming such a
AU2012288422B2 (en) * 2011-07-27 2016-08-11 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
AU2012328415B2 (en) * 2011-10-28 2016-03-17 Baxter Healthcare Sa Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture
US20140275287A1 (en) * 2011-11-01 2014-09-18 Abyrx, Inc. Compositions and Methods for Hemostasis
US8992949B1 (en) 2011-11-17 2015-03-31 Unicare Biomedical, Inc. Biocompatible polymeric compositions having microcrystalline and amorphous components and methods for their manufacture
US20150283296A1 (en) * 2012-12-18 2015-10-08 Novabone Products Llc Bioactive glass with ethylene oxide proplyene oxide block copolymers
US8859007B2 (en) 2013-01-13 2014-10-14 Theracell, Inc. Oxygenated demineralized bone matrix for bone growth
AU2015236008B2 (en) * 2014-03-25 2018-12-20 Genentech, Inc. Methods of preparing a poloxamer for use in cell culture medium
US10201338B1 (en) 2014-09-10 2019-02-12 Abyrx, Inc. Device for the application of surgical materials to tissue
GB2533342A (en) * 2014-12-17 2016-06-22 Ibm Checkpointing module and method for storing checkpoints
EP3381479A1 (en) 2017-03-29 2018-10-03 ARTOSS GmbH Carrier composition for bone substitute materials

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE322412B (en) * 1968-09-10 1970-04-06 Mo Och Domsjoe Ab
US3634305A (en) * 1969-08-08 1972-01-11 Wyandotte Chemicals Corp Water-soluble compositions resistant to shear degradation of the polymer thereof
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
US3903232A (en) * 1973-10-09 1975-09-02 Grace W R & Co Dental and biomedical foams and method
US4038388A (en) * 1974-03-29 1977-07-26 Paterson Zochonis & Company Limited Antimicrobial compositions
US3939261A (en) * 1974-08-30 1976-02-17 Colgate-Palmolive Company Flavored dentifrice
US4027676A (en) * 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4013622A (en) * 1975-06-23 1977-03-22 Cities Service Company Method of reducing breakdown in polyethylene film
DE2546371A1 (en) * 1975-10-16 1977-04-21 Sandoz Ag Solid digitalis glycoside medicaments - contg. polyalkylene glycol and/or a vinyl pyrrolidone (co)polymer
US4125470A (en) 1976-04-02 1978-11-14 Dow Corning Corporation Band-ply lubricant concentrates
US4043344A (en) * 1976-09-20 1977-08-23 American Cyanamid Company Non-absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant
US4047533A (en) * 1976-09-20 1977-09-13 American Cyanamid Company Absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant
US4201216A (en) * 1976-12-15 1980-05-06 Ethicon, Inc. Absorbable coating composition for sutures
JPS55147597A (en) * 1979-05-04 1980-11-17 Mikasa Kagaku Kogyo Kk Treating composition for washing water of stool
US4407953A (en) * 1982-05-24 1983-10-04 Pfizer Inc. Fermentation process for production of alpha-isopropylmalic acid
DE3224784C2 (en) * 1982-07-01 1984-04-26 Siemens Ag, 1000 Berlin Und 8000 Muenchen, De
US4443430A (en) * 1982-11-16 1984-04-17 Ethicon, Inc. Synthetic absorbable hemostatic agent
USRE32208E (en) * 1982-11-16 1986-07-15 Ethicon, Inc. Absorbable hemostatic composition
US4439420A (en) * 1982-11-16 1984-03-27 Ethicon, Inc. Absorbable hemostatic composition
US4470416A (en) * 1983-06-17 1984-09-11 Ethicon, Inc. Copolymers of lactide and/or glycolide with 1,5-dioxepan-2-one
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
DE3663515D1 (en) * 1985-07-02 1989-06-29 Ppg Industries Inc Chemically treated glass fibers
US4716203A (en) * 1986-09-05 1987-12-29 American Cyanamid Company Diblock and triblock copolymers
CA1335873C (en) * 1986-09-20 1995-06-13 Christopher Ansell Adhesive dressings
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5447966A (en) * 1988-07-19 1995-09-05 United States Surgical Corporation Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
GB8802959D0 (en) * 1988-02-09 1988-03-09 Bp Chem Int Ltd Composition for removing asbestos
US5962028A (en) * 1988-04-20 1999-10-05 Norian Corporation Carbonated hydroxyapatite compositions and uses
DE3825211A1 (en) * 1988-07-25 1990-02-01 Henkel Kgaa Improved body-resorbable bone waxes (iii)
DE3832877A1 (en) * 1988-09-28 1990-04-12 Hoechst Ag Organic dispersion polymerises based on ethylenically unsaturated monaments containing polyurethane fryers containing water-soluble and vinyl alcoholic units, process for their preparation and their use
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DE3927113C2 (en) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Agent for the treatment of severe pain conditions and process for their preparation
DE69021991D1 (en) * 1989-10-30 1995-10-05 Fina Research A process for producing polyolefin with controlled morphology by using a metallocene Katalytorsystems.
JP2928892B2 (en) * 1990-11-27 1999-08-03 三洋化成工業株式会社 Surgical adhesive
US5286300A (en) * 1991-02-13 1994-02-15 Man-Gill Chemical Company Rinse aid and lubricant
CA2063278A1 (en) * 1991-06-05 1992-12-06 Jeffrey I. Melzer Composition and process for enhanced drainage of residual aqueous rinse on the external surfaces of plastic parts
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5417808A (en) * 1991-08-30 1995-05-23 Lion Corporation Deinking composition for flotation and deinking method
US6376588B1 (en) * 1991-10-15 2002-04-23 Huntsman Petrochemical Corporation Water soluble mold release composition for elastomeric compounds
US6537574B1 (en) * 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
US5352515A (en) * 1992-03-02 1994-10-04 American Cyanamid Company Coating for tissue drag reduction
CA2092646A1 (en) 1992-03-25 1993-09-26 Ross R. Muth Bioabsorbable blends of a bioabsorbable copolymer and a poly(oxyalkylene)
US5545226A (en) * 1992-05-29 1996-08-13 Porex Technologies Corp. Implants for cranioplasty
US6592859B1 (en) * 1992-08-20 2003-07-15 Ethicon, Inc. Controlled expansion sphincter augmentation media
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
CA2114290C (en) * 1993-01-27 2006-01-10 Nagabushanam Totakura Post-surgical anti-adhesion device
US5503558A (en) * 1993-11-12 1996-04-02 Mcgill University Osseointegration promoting implant composition, implant assembly and method therefor
JPH07179804A (en) 1993-12-22 1995-07-18 Pilot Corp:The Direct-filling ink for water-based ball pen and capped ball pen directly filled with the ink
US5840338A (en) * 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US6017577A (en) * 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US5641502A (en) * 1995-06-07 1997-06-24 United States Surgical Corporation Biodegradable moldable surgical material
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
JPH09143093A (en) * 1995-11-17 1997-06-03 Hoechst Japan Ltd Cartilage/bone-inductive restoring material
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
TW358116B (en) * 1996-12-09 1999-05-11 Mitsubishi Pencil Co Ballpen aqueous ink component
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
AU9027298A (en) * 1997-08-20 1999-03-08 Lxr Biotechnology Inc. Compositions containing polyethylene glycol and uses thereof
US6309659B1 (en) * 1997-09-02 2001-10-30 Gensci Orthobiologics, Inc. Reverse phase connective tissue repair composition
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
US6417247B1 (en) * 1997-10-14 2002-07-09 Beth L. Armstrong Polymer/ceramic composites
US6437018B1 (en) * 1998-02-27 2002-08-20 Musculoskeletal Transplant Foundation Malleable paste with high molecular weight buffered carrier for filling bone defects
US5968480A (en) * 1998-07-09 1999-10-19 Colgate Palmolive Company Oral composition exhibiting enhanced antiplaque efficacy
CA2244017A1 (en) * 1998-07-28 2000-01-28 Stephane Tetreault Moisture-curable adhesive suture strip
US6406498B1 (en) * 1998-09-04 2002-06-18 Bionx Implants Oy Bioactive, bioabsorbable surgical composite material
AU768641B2 (en) * 1998-10-12 2003-12-18 Massachusetts Institute Of Technology Composites for tissue regeneration and methods of manufacture thereof
US7168086B1 (en) * 1998-11-30 2007-01-23 Microsoft Corporation Proxy for video on demand server control
WO2000035276A1 (en) * 1998-12-18 2000-06-22 Medlogic Global Corporation Cyanoacrylate compositions comprising a soluble antimicrobial agent
US6762339B1 (en) * 1999-05-21 2004-07-13 3M Innovative Properties Company Hydrophilic polypropylene fibers having antimicrobial activity
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
WO2001032101A1 (en) 1999-10-29 2001-05-10 Children's Hospital Los Angeles Bone hemostasis method and materials
US6328990B1 (en) * 1999-11-12 2001-12-11 The Trustees Of The University Of Pennsylvania Bioactive, degradable composite for tissue engineering
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
JP2001172411A (en) * 1999-12-20 2001-06-26 Toyobo Co Ltd Thermoplastic polyester elastomer film
US20020025340A1 (en) * 2000-08-30 2002-02-28 Dyer Wallace K. Methods and compositions for tissue augmentation
US6296607B1 (en) * 2000-10-20 2001-10-02 Praxis, Llc. In situ bulking device
JP2002322235A (en) * 2001-04-24 2002-11-08 Nippon Polyurethane Ind Co Ltd Method for producing soft polyurethane foam
US6685956B2 (en) * 2001-05-16 2004-02-03 The Research Foundation At State University Of New York Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications
US20030082235A1 (en) * 2001-08-13 2003-05-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
IL151288D0 (en) * 2001-08-27 2003-04-10 Yissum Res Dev Co Multi-component reverse thermo-sensitive polymeric systems
US20030190336A1 (en) * 2002-03-18 2003-10-09 Adams Christine Helga Personal care compositions comprising solid particles enterapped in a gel network
JP4324341B2 (en) * 2002-03-22 2009-09-02 ディバーシー・アイピー・インターナショナル・ビー・ヴイ For automatic dishwashing liquid detergent composition
WO2003080119A1 (en) * 2002-03-26 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Responsive biomedical composites
AU2003298626A1 (en) * 2002-11-12 2004-06-03 The Polymer Technology Group Incorporated Control of polymer surface molecular architecture via amphipathic endgroups
WO2004071451A2 (en) 2003-02-12 2004-08-26 Ceremed, Inc. Random alkylene oxide copolymers for medical and surgical utilities
IL155866D0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
FR2859988A1 (en) 2003-09-18 2005-03-25 Nanoledge Dispersions of carbon nanotubes in organic solvents, useful in production of composites with e.g. electroconductive properties, prepared using stabilizing combination of surfactant and polymer
US20060008609A1 (en) * 2004-01-26 2006-01-12 Snyder Glenn E Sandwich panel and method of manufacturing same
WO2005094724A1 (en) * 2004-03-29 2005-10-13 Promethean Surgical Devices Llc Surgical adhesive formulations and methods of preparation
ITBO20040629A1 (en) * 2004-10-14 2005-01-14 Marchesini Group Spa System for the transmission of motion between separate bodies by a partition wall
CA2526541C (en) 2004-12-01 2013-09-03 Tyco Healthcare Group Lp Novel biomaterial drug delivery and surface modification compositions

Also Published As

Publication number Publication date
US20060100370A1 (en) 2006-05-11
US7553913B2 (en) 2009-06-30
US20110002915A1 (en) 2011-01-06
CN1780596A (en) 2006-05-31
EP1596767B1 (en) 2018-10-03
WO2004071451A3 (en) 2005-09-22
US20060140904A1 (en) 2006-06-29
AU2004211991A1 (en) 2004-08-26
CN1780596B (en) 2010-12-15
JP2006521425A (en) 2006-09-21
JP5282150B2 (en) 2013-09-04
US20090238758A1 (en) 2009-09-24
EP1596767A4 (en) 2010-10-27
EP1596767A2 (en) 2005-11-23
US9919074B2 (en) 2018-03-20
WO2004071451A2 (en) 2004-08-26
US8124687B2 (en) 2012-02-28
US7829616B2 (en) 2010-11-09
WO2004071452A3 (en) 2004-11-11
EP1601326A2 (en) 2005-12-07
JP5508661B2 (en) 2014-06-04
US20120219497A1 (en) 2012-08-30
TWI367113B (en) 2012-07-01
ES2695401T3 (en) 2019-01-04
JP2012136703A (en) 2012-07-19
EP1601326A4 (en) 2011-05-11
TW200507826A (en) 2005-03-01
AU2004211991B2 (en) 2011-03-31
TW200507888A (en) 2005-03-01
WO2004071452A2 (en) 2004-08-26
CA2515292C (en) 2015-09-29
US20110002974A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
Holland et al. Osteochondral repair in the rabbit model utilizing bilayered, degradable oligo (poly (ethylene glycol) fumarate) hydrogel scaffolds
Alderman Sterile plaster of paris as an implant in the infrabony environment: a preliminary study
Fu et al. Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration
Kuehn et al. Acrylic bone cements: composition and properties
US5413792A (en) Mucoadhesive polysiloxane paste-like base and preparation
CA2423999C (en) Compositions and medical devices utilizing bioabsorbable liquid polymers
US6051247A (en) Moldable bioactive compositions
AU2003237198B8 (en) Allograft bone composition having a gelatin binder
US20020197242A1 (en) Composition for filling bone defects
US20120009230A1 (en) Malleable implants containing demineralized bone matrix
US6911212B2 (en) Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects
EP1246651B1 (en) Bioactive and osteoporotic bone cement
Steadman et al. Tissue-engineered collagen meniscus implants: 5-to 6-year feasibility study results
Adhikari et al. Biodegradable injectable polyurethanes: synthesis and evaluation for orthopaedic applications
US6312666B1 (en) Methods of whitening teeth
US6576249B1 (en) Bone putty and method
US7955616B2 (en) Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20050074495A1 (en) Compositions of polyacids and methods for their use in reducing adhesions
US3987163A (en) Polystyrene sulfonate containing opthalmic solutions
US8652503B2 (en) Bone paste
KR101401873B1 (en) Rapidly acting dry sealant and methods for use and manufacture
KR101100045B1 (en) Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US5962549A (en) Bioactive composite material for repair of hard and soft tissues
US4443430A (en) Synthetic absorbable hemostatic agent
EP0747072B1 (en) Biodegradable moldable surgical material

Legal Events

Date Code Title Description
EEER Examination request